<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">89999</article-id><article-id pub-id-type="doi">10.7554/eLife.89999</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.89999.4</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Early acquisition of S-specific Tfh clonotypes after SARS-CoV-2 vaccination is associated with the longevity of anti-S antibodies</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-312704"><name><surname>Lu</surname><given-names>Xiuyuan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0784-2871</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-322500"><name><surname>Hayashi</surname><given-names>Hiroki</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-322501"><name><surname>Ishikawa</surname><given-names>Eri</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322502"><name><surname>Takeuchi</surname><given-names>Yukiko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-322503"><name><surname>Dychiao</surname><given-names>Julian Vincent Tabora</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-21566"><name><surname>Nakagami</surname><given-names>Hironori</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4494-3601</contrib-id><email>nakagami@gts.med.osaka-u.ac.jp</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-234537"><name><surname>Yamasaki</surname><given-names>Sho</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5184-6917</contrib-id><email>yamasaki@biken.osaka-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University</institution></institution-wrap><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Department of Health Development and Medicine, Osaka University Graduate School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University</institution></institution-wrap><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Center for Infectious Disease Education and Research (CiDER), Osaka University</institution></institution-wrap><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Morio</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051k3eh31</institution-id><institution>Tokyo Medical and Dental University</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Takayanagi</surname><given-names>Hiroshi</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>The University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>05</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP89999</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-06-29"><day>29</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-06-07"><day>07</day><month>06</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.06.06.543529"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-10-11"><day>11</day><month>10</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.89999.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-02-28"><day>28</day><month>02</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.89999.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-15"><day>15</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.89999.3"/></event></pub-history><permissions><copyright-statement>© 2023, Lu, Hayashi, Ishikawa et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Lu, Hayashi, Ishikawa et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-89999-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-89999-figures-v1.pdf"/><abstract><p>SARS-CoV-2 vaccines have been used worldwide to combat COVID-19 pandemic. To elucidate the factors that determine the longevity of spike (S)-specific antibodies, we traced the characteristics of S-specific T cell clonotypes together with their epitopes and anti-S antibody titers before and after BNT162b2 vaccination over time. T cell receptor (TCR) αβ sequences and mRNA expression of the S-responded T cells were investigated using single-cell TCR- and RNA-sequencing. Highly expanded 199 TCR clonotypes upon stimulation with S peptide pools were reconstituted into a reporter T cell line for the determination of epitopes and restricting HLAs. Among them, we could determine 78 S epitopes, most of which were conserved in variants of concern (VOCs). After the 2nd vaccination, T cell clonotypes highly responsive to recall S stimulation were polarized to follicular helper T (Tfh)-like cells in donors exhibiting sustained anti-S antibody titers (designated as ‘sustainers’), but not in ‘decliners’. Even before vaccination, S-reactive CD4<sup>+</sup> T cell clonotypes did exist, most of which cross-reacted with environmental or symbiotic microbes. However, these clonotypes contracted after vaccination. Conversely, S-reactive clonotypes dominated after vaccination were undetectable in pre-vaccinated T cell pool, suggesting that highly responding S-reactive T cells were established by vaccination from rare clonotypes. These results suggest that de novo acquisition of memory Tfh-like cells upon vaccination may contribute to the longevity of anti-S antibody titers.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>vaccine</kwd><kwd>SARS-CoV-2</kwd><kwd>T cell response</kwd><kwd>Tfh cells</kwd><kwd>clonotypic tracing</kwd><kwd>antibody longevity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP223fa627002</award-id><principal-award-recipient><name><surname>Yamasaki</surname><given-names>Sho</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP21ym0126049</award-id><principal-award-recipient><name><surname>Nakagami</surname><given-names>Hironori</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP20H00505</award-id><principal-award-recipient><name><surname>Yamasaki</surname><given-names>Sho</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP223fa727001</award-id><principal-award-recipient><name><surname>Yamasaki</surname><given-names>Sho</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP23ym0126049</award-id><principal-award-recipient><name><surname>Yamasaki</surname><given-names>Sho</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP22H05182</award-id><principal-award-recipient><name><surname>Yamasaki</surname><given-names>Sho</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP22H05183</award-id><principal-award-recipient><name><surname>Yamasaki</surname><given-names>Sho</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Clonotypic tracing of SARS-CoV-2–responsive T cells reveals vaccination-induced dominant Tfh clonotypes, not pre-existing T cells, associated with sustained humoral response, and can serve as an index of antigen-specific antibody longevity.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The pandemic COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has expanded worldwide (<xref ref-type="bibr" rid="bib15">Hu et al., 2021</xref>). Many types of vaccines have been developed or in basic and clinical phases to combat infection and deterioration of COVID-19 (<xref ref-type="bibr" rid="bib9">Creech et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Krammer, 2020</xref>). Among them, messenger ribonucleic acid (mRNA) vaccines, BNT162b2/Comirnaty and mRNA-1273/Spikevax, have been approved with over 90% efficacy at 2 months post-2nd dose vaccination (<xref ref-type="bibr" rid="bib4">Baden et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Polack et al., 2020</xref>), and widely used. Pathogen-specific antibodies are one of the most efficient components to prevent infection. Yet, mRNA vaccine-induced serum antibody titer is known to be waning over 6 months (<xref ref-type="bibr" rid="bib26">Levin et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Pegu et al., 2021</xref>). Accordingly, the effectiveness of the vaccines decreases over time, and thus multiple doses and repeated boosters are necessary (<xref ref-type="bibr" rid="bib1">Andrews et al., 2022</xref>).</p><p>The production and sustainability of spike (S)-specific antibody could be related to multiple factors, especially in the case of humans (<xref ref-type="bibr" rid="bib8">Collier et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Levin et al., 2021</xref>). Among them, the characteristics of SARS-CoV-2-specific T cells are critically involved in the affinity and longevity of the antibodies (<xref ref-type="bibr" rid="bib10">Crotty, 2019</xref>; <xref ref-type="bibr" rid="bib34">Nelson et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Terahara et al., 2022</xref>). Elucidation of the key factors of T cell responses that contribute to the durable immune responses induced by vaccination would provide valuable information for the vaccine development in the future. However, the relationship between antibody sustainability and the types of antigen-specific T cells has not been investigated in a clonotype resolution.</p><p>Recent studies reported that S-reactive T cells pre-existed before exposure to SARS-CoV-2 (<xref ref-type="bibr" rid="bib14">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Mateus et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Sekine et al., 2020</xref>). Common cold human coronaviruses (HCoVs) including strains 229E, NL63, OC43, and HKU1 are considered major cross-reactive antigens that primed these pre-existing T cells (<xref ref-type="bibr" rid="bib6">Becerra-Artiles et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Low et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Loyal et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">Mateus et al., 2020</xref>), while bacterial cross-reactive antigens were also reported (<xref ref-type="bibr" rid="bib5">Bartolo et al., 2022</xref>; <xref ref-type="bibr" rid="bib29">Lu et al., 2021</xref>). However, the functional relevance of cross-reactive T cells during infection or vaccination is still in debate.</p><p>In this study, both humoral and cellular immune responses were evaluated at 3, 6, and 24 weeks after BNT162b2/Comirnaty vaccination. S-specific T cells before and after vaccination were analyzed on clonotype level using single-cell-based T cell receptor (TCR) and RNA sequencing to determine their characteristics and epitopes in antibody sustainers and decliners. These analyses suggest the importance of early acquisition of S-specific Tfh cells in the longevity of antibodies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SARS-CoV-2 mRNA vaccine elicits transient humoral immunity</title><p>Blood samples were collected from a total of 43 individuals (<xref ref-type="table" rid="table1">Table 1</xref>) who had no SARS-CoV-2 infection history when they received two doses of SARS-CoV-2 mRNA vaccine BNT162b2. Samples were taken before and after the vaccination (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Consistent with the previous report (<xref ref-type="bibr" rid="bib38">Polack et al., 2020</xref>), most participants exhibited more severe side effects after 2nd dose of vaccination than 1st dose locally (<xref ref-type="table" rid="table2">Table 2</xref>) and systemically (<xref ref-type="table" rid="table3">Table 3</xref>). At 3 weeks, anti-S IgG antibody titer increased in most participants. At 6 weeks, anti-S antibody titer was at its peak. S antibody titer gradually decreased over 24 weeks (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The antibody titer was reduced by 56.8% on average. Donors of different sexes or age groups showed no significant difference in anti-S antibody titer (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The neutralization activity of the post-vaccinated sera showed similar tendency with the anti-S antibody titer during the study period (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The above results indicate that the mRNA vaccine effectively activated humoral immune responses in healthy individuals, but decreased by 24 weeks over time as reported (<xref ref-type="bibr" rid="bib26">Levin et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Pegu et al., 2021</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>SARS-CoV-2 mRNA vaccine elicits transient humoral immunity.</title><p>(<bold>A</bold>) Vaccination and sampling timeline of blood donors in this study. (<bold>B</bold>) Anti-S IgG titer of serum samples was determined by ELISA. Mean ± SEM (left) and individual data (right) are shown. *, p&lt;0.05 vs. Pre, 3 weeks, 24 weeks, respectively. (<bold>C</bold>) Neutralization activity (ID50) of serum samples was determined by pseudo-virus assay. Mean ± SEM (left) and individual data (right) are shown. *, p&lt;0.05 vs 3 weeks, 24 weeks, respectively. Wks, weeks.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Humoral immune response of BNT162b2 vaccinees.</title><p>(<bold>A, B</bold>) Anti-S IgG titer from all donors at 6 weeks after vaccination was compared between male and female vaccinees (<bold>A</bold>) or among different age groups (20–39, 40–49, 50–59, 60–69) (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig1-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Demographic data of the participants.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Percentage (number)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Total number</bold></td><td align="left" valign="bottom">100% (43)</td></tr><tr><td align="left" valign="bottom"><bold>Age group</bold></td><td align="left" valign="bottom"/></tr><tr><td align="char" char="ndash" valign="bottom">20–39</td><td align="left" valign="bottom">39.5% (17)</td></tr><tr><td align="char" char="ndash" valign="bottom">40–49</td><td align="left" valign="bottom">30.2% (13)</td></tr><tr><td align="char" char="ndash" valign="bottom">50–59</td><td align="left" valign="bottom">25.6% (11)</td></tr><tr><td align="char" char="ndash" valign="bottom">60–69</td><td align="left" valign="bottom">4.7% (2)</td></tr><tr><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Male</td><td align="left" valign="bottom">60.5% (26)</td></tr><tr><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">39.5% (17)</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Demographic data of the reported clinical adverse effects (at injection site).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Percentage (number)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Swelling (injection site</bold>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="char" char="." valign="bottom">27.9% (12)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="char" char="." valign="bottom">51.2% (22)</td></tr><tr><td align="left" valign="bottom"><bold>Sore/pain (injection site</bold>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="char" char="." valign="bottom">88.4% (38)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="char" char="." valign="bottom">86.0% (37)</td></tr><tr><td align="left" valign="bottom"><bold>Warmth (injection site</bold>)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="char" char="." valign="bottom">32.6% (14)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="char" char="." valign="bottom">41.9% (18)</td></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Demographic data of the reported clinical adverse effects (systemic symptoms).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Percentage (number)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Fever</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild (37.5 °C ≥)</td><td align="left" valign="bottom">2.3% (1)</td></tr><tr><td align="left" valign="bottom">Severe (≥38.0 °C)</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild (37.5 °C ≥)</td><td align="left" valign="bottom">25.6% (11)</td></tr><tr><td align="left" valign="bottom">Severe (≥38.0 °C)</td><td align="left" valign="bottom">23.3% (10)</td></tr><tr><td align="left" valign="bottom"><bold>Fatigue</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">18.6% (8)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">67.4% (29)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">18.6% (8)</td></tr><tr><td align="left" valign="bottom"><bold>Headache</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">7.0% (3)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">32.6% (14)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">7.0% (3)</td></tr><tr><td align="left" valign="bottom"><bold>Chill</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">4.7% (2)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">23.3% (10)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">9.3% (4)</td></tr><tr><td align="left" valign="bottom"><bold>Nausea</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">4.7% (2)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom"><bold>Diarrhea</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom"><bold>Muscle pain</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">48.8% (21)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">55.8% (24)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">4.7% (2)</td></tr><tr><td align="left" valign="bottom"><bold>Joint pain</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">After 1st dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">4.7% (2)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">0% (0)</td></tr><tr><td align="left" valign="bottom">After 2nd dose</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Mild</td><td align="left" valign="bottom">25.6% (11)</td></tr><tr><td align="left" valign="bottom">Severe</td><td align="left" valign="bottom">4.7% (2)</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Antibody sustainers had highly expanded S-reactive Tfh clonotypes</title><p>To address the role of T cells in maintaining the antibody titer, we analyzed the S-responsive T cells in the post-vaccination samples from eight donors, among whom four donors showed relatively sustained anti-S antibody titer during 6 weeks to 24 weeks (reduction &lt;30%; sustainers, donors #8, #25, #27, and #28), while the other four donors showed largely declined anti-S antibody titer (reduction &gt;80%; decliners, donors #4, #13, #15, and #17; <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). The possibility of SARS-CoV-2 infection of sustainers was ruled out by analyzing anti-nucleocapsid protein (N) antibody titer in the sera samples at 24 weeks (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Antibody sustainability did not correlate with bulk T cell responses to S protein, such as IFNγ production (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Antibody sustainers had highly expanded S-reactive Tfh clonotypes.</title><p>(<bold>A</bold>) Anti-S IgG titer of serum samples from sustainers and decliners is shown individually. (<bold>B, C, E, F</bold>) UMAP projection of T cells in single-cell analysis of post-vaccinated samples collected from all donors. Each dot corresponds to a single cell and is colored according to the samples from different time points of donors. All samples together with annotated cell types (<bold>B</bold>), samples grouped by donor type (decliners and sustainers) (<bold>C</bold>), top 16 expanded clonotypes (16 clonotypes that had the most cell numbers from each donor) grouped by donor type (<bold>E</bold>), and top 16 expanded clonotypes grouped by time point and donor type (<bold>F</bold>) are shown. Tcm, central memory T cells; Tem, effector memory T cells; Treg, regulatory T cells; γδT, γδ T cells. (<bold>D</bold>) Tfh signature score and expression levels of the canonical Tfh cell markers, <italic>IL21</italic>, <italic>ICOS</italic>, <italic>PDCD1</italic> and <italic>CD200</italic>, are shown as heat maps in the UMAP plot.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Humoral and cellular immune responses of sustainers and decliners.</title><p>(<bold>A</bold>) Demographic data and magnitude of anti-S IgG titer reduction of the sustainers and decliners. Anti-S IgG titer reduction is calculated as the titers at (6 weeks – 24 weeks) /6 weeks. (<bold>B</bold>) Anti-N IgG titer of serum samples from sustainers at 24 weeks after vaccination. (<bold>C</bold>) S-specific IFNγ release from bulk CD4<sup>+</sup> T cells (left) or CD4<sup>+</sup> and CD8<sup>+</sup> T cells (right) of sustainers (red) and decliners (blue) was measured using QuantiFERON.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Sustainer individuals had more cells in the circled region than decliner individuals.</title><p>(<bold>A</bold>) UMAP projection of single-cell analysis of post-vaccinated samples shown in individuals. (<bold>B</bold>) The percentage of circled cells in (<bold>A</bold>) in CD4<sup>+</sup> T cells of each individual is shown. p value was calculated using t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig2-figsupp2-v1.tif"/></fig></fig-group><p>To enrich the S-reactive T cells, we labeled the peripheral blood mononuclear cells (PBMCs) with a cell proliferation tracer and stimulated the PBMCs with an S peptide pool for 10 days. Proliferated T cells were sorted and analyzed by single-cell TCR- and RNA-sequencing (scTCR/RNA-seq). Clustering analysis was done with pooled samples of three time points from eight donors, and various T cell subtypes were identified (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="scode1">Source code 1</xref>). We found that, overall, the S-reactive T cells did not skew to any particular T cell subset (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). However, by grouping the cells from decliners and sustainers separately, we found difference in the frequency of the cells within the circled population (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), and overall, the sustainer individuals had more cells in this region (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). These cells showed high Tfh signature scores and expressed characteristic genes of Tfh cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). This tendency became more pronounced when we selected highly expanded (top 16) clonotypes in each donor (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). In sustainers, S-specific Tfh clusters appeared from 6 weeks (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), suggesting that vaccine-induced Tfh-like cells that have potency of deriving to Tfh cells were established immediately after 2nd vaccination.</p></sec><sec id="s2-3"><title>Identification of dominant S epitopes recognized by vaccine-induced T cell clonotypes</title><p>To elucidate the epitopes of the highly expanded clonotypes, we reconstituted their TCRs into a T cell hybridoma lacking endogenous TCRs and having an NFAT-GFP reporter gene. These cell lines were stimulated with S peptides using transformed autologous B cells as antigen-presenting cells (APCs). The epitopes of 53 out of 128 reconstituted clonotypes were successfully determined (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>). Epitopes of expanded Tfh cells were not limited in any particular region of S protein (<xref ref-type="fig" rid="fig3">Figure 3</xref>). About 72% of these epitopes conserved in Delta and Omicron variants (<xref ref-type="table" rid="table4 table5">Tables 4 and 5</xref>). Within the rest of 28% of epitopes which were mutated in variants of concern (VOCs), although some mutated epitopes located in the receptor-binding domain (RBD) of VOCs lost antigenicity, recognition of most epitopes outside the RBD region was maintained or rather increased in the variants (<xref ref-type="table" rid="table5">Table 5</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). These results suggest that the majority of S-reactive clonotypes after vaccination can respond to antibody-escaping VOCs.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The location of S epitopes recognized by top expanded T clonotypes from post-vaccination samples.</title><p>T cell S epitopes recognized by top expanded TCR clonotypes in post-vaccinated samples from sustainers and decliners are mapped by their locations in S protein. Each short bar indicates a 15-mer peptide that activated the TCRs. Epitopes are shown in different colors according to the subsets of the T cells they activated. Relative frequencies of the T cell subsets are shown in pie charts. Numbers of identified epitopes recognized by a dominant T subset in sustainers (Tfh) are shown in blue bars. NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connector domain; HR2, heptad repeat 2; TM, transmembrane domain.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Determination of S epitopes for post-vaccinated T cell clonotypes expanded in sustainers and decliners.</title><p>(<bold>A, B</bold>) Reporter cells expressing TCR clonotypes expanded in sustainers (<bold>A</bold>) and decliners (<bold>B</bold>) were stimulated with different S peptide in the presence of APCs for overnight, and analyzed for GFP and CD69 expression. Data are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Determination of restricting HLAs for post-vaccinated T cell clonotypes expanded in sustainers and decliners.</title><p>(<bold>A, B</bold>) Reporter cells expressing TCR clonotypes expanded in sustainers (<bold>A</bold>) and decliners (<bold>B</bold>) were stimulated with epitope peptides in the presence of APCs expressing various HLA alleles. Data are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Determination of mutated epitope antigenicity for post-vaccinated T cell clonotypes expanded in sustainers and decliners.</title><p>(<bold>A, B</bold>) Reporter cells expressing TCR clonotypes expanded in sustainers (<bold>A</bold>) and decliners (<bold>B</bold>) were stimulated with epitope peptides from the Wuhan strain and corresponding peptides from VOCs in the presence of APCs. Data are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig3-figsupp3-v1.tif"/></fig></fig-group><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>TCR clonotypes expanded in post-vaccinated samples and their TCR usages, epitopes and restricting HLAs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Donor</th><th align="left" valign="bottom">Clonotype</th><th align="left" valign="bottom">TRBV</th><th align="left" valign="bottom">CDR3β</th><th align="left" valign="bottom">TRBJ</th><th align="left" valign="bottom">TRAV</th><th align="left" valign="bottom">CDR3α</th><th align="left" valign="bottom">TRAJ</th><th align="left" valign="bottom">S epitope<xref ref-type="table-fn" rid="table4fn1">*</xref></th><th align="left" valign="bottom">Restricting HLA</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="10">#8</td><td align="left" valign="bottom">Post_4</td><td align="left" valign="bottom">11–2</td><td align="left" valign="bottom">CASSPTGTNEKLFF</td><td align="char" char="ndash" valign="bottom">1–4</td><td align="char" char="ndash" valign="bottom">13–1</td><td align="left" valign="bottom">CAGGADGLTF</td><td align="char" char="." valign="bottom">45</td><td align="left" valign="bottom">SFSTFKCYGVSPTKL<sub>373–387</sub><xref ref-type="table-fn" rid="table4fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">DRA-DRB1*15:02</td></tr><tr><td align="left" valign="bottom">Post_5</td><td align="left" valign="bottom">19</td><td align="left" valign="bottom">CASSGRPEGPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="." valign="bottom">20</td><td align="left" valign="bottom">CAVLNQAGTALIF</td><td align="char" char="." valign="bottom">15</td><td align="left" valign="bottom">FKIYSKHTPIN<sub>201–211</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td></tr><tr><td align="left" valign="bottom">Post_6</td><td align="left" valign="bottom">11–2</td><td align="left" valign="bottom">CASSLEGTEAFF</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CAESRYMGRRALTF</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">FQFCNDPFLGVYYHK<sub>133–147</sub></td><td align="left" valign="bottom">DPA1*01:03-DPB1*04:02</td></tr><tr><td align="left" valign="bottom">Post_7</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">CAGLAGVDTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CAERVGRRALTF</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">YSVLYNSASFSTFKC<sub>365–379</sub></td><td align="left" valign="bottom">A*24:02</td></tr><tr><td align="left" valign="bottom">Post_8</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSATRDRRSYNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">12–2</td><td align="left" valign="bottom">CAVLTNTGNQFYF</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">LLQYGSFCTQLNRAL<sub>753–767</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td></tr><tr><td align="left" valign="bottom">Post_9</td><td align="left" valign="bottom">7–9</td><td align="left" valign="bottom">CASSLLGEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">CAGAGGTSYGKLTF</td><td align="char" char="." valign="bottom">52</td><td align="left" valign="bottom">KRFDNPVLPFN<sub>77–87</sub></td><td align="left" valign="bottom">DPA1*02:02-DPB1*05:01</td></tr><tr><td align="left" valign="bottom">Post_10</td><td align="left" valign="bottom">6–1</td><td align="left" valign="bottom">CASSEGASNQPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="ndash" valign="bottom">12–1</td><td align="left" valign="bottom">CVVNKGSSASKIIF</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">LLQYGSFCTQL<sub>753–763</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td></tr><tr><td align="left" valign="bottom">Post_12</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSAYSIYNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALSMNTGFQKLVF</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">PPAYTNSFTRGVYYP<sub>25–39</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td></tr><tr><td align="left" valign="bottom">Post_14</td><td align="left" valign="bottom">19</td><td align="left" valign="bottom">CASRPNRGDNSPLHF</td><td align="char" char="ndash" valign="bottom">1–6</td><td align="char" char="ndash" valign="bottom">12–1</td><td align="left" valign="bottom">CVVSIGFGNVLHC</td><td align="char" char="." valign="bottom">35</td><td align="left" valign="bottom">CSNLLLQYGSFCTQL<sub>749–763</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">CASSLMGGAYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="ndash" valign="bottom">8–6</td><td align="left" valign="bottom">CAVRRGGSGGSNYKLTF</td><td align="char" char="." valign="bottom">53</td><td align="left" valign="bottom">SKRSFIEDLLFNKVT<sub>813–827</sub></td><td align="left" valign="bottom">DPA1*01:03-DPB1*04:02</td></tr><tr><td align="left" valign="bottom" rowspan="3">#25</td><td align="left" valign="bottom">Post_7</td><td align="left" valign="bottom">7–9</td><td align="left" valign="bottom">CAPSNANTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="ndash" valign="bottom">12–1</td><td align="left" valign="bottom">CVVNEADKLIF</td><td align="char" char="." valign="bottom">34</td><td align="left" valign="bottom">YLQPRTFLLK<sub>269–278</sub></td><td align="left" valign="bottom">A*02:01</td></tr><tr><td align="left" valign="bottom">Post_12</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSARDVEVGSGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">CLVGPYNQGGKLIF</td><td align="char" char="." valign="bottom">23</td><td align="left" valign="bottom">TGVLTESNKKFLPFQ<sub>549–563</sub></td><td align="left" valign="bottom">DRA-DRB1*14:54</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">3–1</td><td align="left" valign="bottom">CASSPLSGSSYEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="ndash" valign="bottom">12–1</td><td align="left" valign="bottom">CVVGTDSWGKLQF</td><td align="char" char="." valign="bottom">24</td><td align="left" valign="bottom">TNGTKRFDNPVLPFN<sub>73–87</sub></td><td align="left" valign="bottom">DPA1*02:02-DPB1*05:01/<break/>DPA1*01:03-DPB1*05:01</td></tr><tr><td align="left" valign="bottom" rowspan="11">#27</td><td align="left" valign="bottom">Post_1</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSAIAGDADTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALTSAAGNKLTF</td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">NQFNSAIGKIQ<sub>925–935</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td></tr><tr><td align="left" valign="bottom">Post_2</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">CAWNLGGGNQPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="ndash" valign="bottom">8–2</td><td align="left" valign="bottom">CVVSERASSYKLIF</td><td align="char" char="." valign="bottom">12</td><td align="left" valign="bottom">SKRSFIEDLLFNKVT<sub>813–827</sub></td><td align="left" valign="bottom">DPA1*02:02-DPB1*04:02</td></tr><tr><td align="left" valign="bottom">Post_3</td><td align="left" valign="bottom">5–4</td><td align="left" valign="bottom">CASSQGQGSYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">CLVGDSDTGRRALTF</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">NFTISVTTEIL<sub>717–727</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td></tr><tr><td align="left" valign="bottom">Post_5</td><td align="left" valign="bottom">7–2</td><td align="left" valign="bottom">CASGTGSYNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">12–2</td><td align="left" valign="bottom">CAVKRGNQGGKLIF</td><td align="char" char="." valign="bottom">23</td><td align="left" valign="bottom">STEIYQAGSTPCNGV<sub>469–483</sub></td><td align="left" valign="bottom">DRA-DRB1*04:03</td></tr><tr><td align="left" valign="bottom">Post_7</td><td align="left" valign="bottom">6–6</td><td align="left" valign="bottom">CASRLPGNRAQPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="." valign="bottom">36/DV7</td><td align="left" valign="bottom">CAVESGSSNTGKLIF</td><td align="char" char="." valign="bottom">37</td><td align="left" valign="bottom">KSNIIRGWIFGTTLD<sub>97–111</sub></td><td align="left" valign="bottom">DRA-DRB4*01:03</td></tr><tr><td align="left" valign="bottom">Post_8</td><td align="left" valign="bottom">6–5</td><td align="left" valign="bottom">CASSYSGGTVTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="." valign="bottom">41</td><td align="left" valign="bottom">CAVGIRGNEKLTF</td><td align="char" char="." valign="bottom">48</td><td align="left" valign="bottom">KVFRSSVLHST<sub>41–51</sub></td><td align="left" valign="bottom">DRA-DRB1*04:03</td></tr><tr><td align="left" valign="bottom">Post_9</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSARDGQTATNEKLFF</td><td align="char" char="ndash" valign="bottom">1–4</td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">CATNAGGTSYGKLTF</td><td align="char" char="." valign="bottom">52</td><td align="left" valign="bottom">EIRASANLAAT<sub>1017–1027</sub></td><td align="left" valign="bottom">DRA-DRB1*04:03</td></tr><tr><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">CAWSVKGFPSQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">CALGSTSNTGKLIF</td><td align="char" char="." valign="bottom">37</td><td align="left" valign="bottom">EIRASANLAAT<sub>1017–1027</sub></td><td align="left" valign="bottom">DRA-DRB1*04:03</td></tr><tr><td align="left" valign="bottom">Post_13</td><td align="left" valign="bottom">5–6</td><td align="left" valign="bottom">CASSSRTGYNSPLHF</td><td align="char" char="ndash" valign="bottom">1–6</td><td align="char" char="." valign="bottom">27</td><td align="left" valign="bottom">CAGAKGSGTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">STEIYQAGSTPCNGV<sub>469–483</sub></td><td align="left" valign="bottom">DRA-DRB1*04:03</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">5–5</td><td align="left" valign="bottom">CASSSDRNYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="ndash" valign="bottom">12–1</td><td align="left" valign="bottom">CVVNMVTGGYNKLIF</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">NFTISVTTEILPVSM<sub>717–731</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td></tr><tr><td align="left" valign="bottom">Post_16</td><td align="left" valign="bottom">7–9</td><td align="left" valign="bottom">CASSSQPGLAGVKIGNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CAEIPPPSNTGKLIF</td><td align="char" char="." valign="bottom">37</td><td align="left" valign="bottom">ISGINASVVNIQKEI<sub>1169–1183</sub></td><td align="left" valign="bottom">DRA-DRB1*04:03</td></tr><tr><td align="left" valign="bottom" rowspan="6">#28</td><td align="left" valign="bottom">Post_5</td><td align="left" valign="bottom">3–1</td><td align="left" valign="bottom">CASSQGGSEKLFF</td><td align="char" char="ndash" valign="bottom">1–4</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="left" valign="bottom">CAVGGNTDKLIF</td><td align="char" char="." valign="bottom">34</td><td align="left" valign="bottom">LVKNKCVNFNF<sub>533–543</sub></td><td align="left" valign="bottom">DRA-DRB3*03:01</td></tr><tr><td align="left" valign="bottom">Post_10</td><td align="left" valign="bottom">12–3</td><td align="left" valign="bottom">CASSSGRTGFGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">30</td><td align="left" valign="bottom">CGTEFGSEKLVF</td><td align="char" char="." valign="bottom">57</td><td align="left" valign="bottom">VIRGDEVRQIA<sub>401–411</sub></td><td align="left" valign="bottom">DRA-DRB3*03:01</td></tr><tr><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">5–8</td><td align="left" valign="bottom">CASSLQKTTGPSYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="ndash" valign="bottom">8–6</td><td align="left" valign="bottom">CAVSPYTGRRALTF</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">SVYAWNRKRIS<sub>349–359</sub></td><td align="left" valign="bottom">DRA-DRB1*13:02</td></tr><tr><td align="left" valign="bottom">Post_12</td><td align="left" valign="bottom">18</td><td align="left" valign="bottom">CASSASVDPTEAFF</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="left" valign="bottom">CASFTGGGNKLTF</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">KSTNLVKNKCVNFNF<sub>529–543</sub></td><td align="left" valign="bottom">DRA-DRB3*03:01</td></tr><tr><td align="left" valign="bottom">Post_14</td><td align="left" valign="bottom">7–6</td><td align="left" valign="bottom">CASSLSGTGGTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">CLVGDMRSGGGADGLTF</td><td align="char" char="." valign="bottom">45</td><td align="left" valign="bottom">PFGEVFNATRFASVY<sub>337–351</sub></td><td align="left" valign="bottom">B*40:01</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">6–2</td><td align="left" valign="bottom">CASSYPPSGGRTGFGEAFF</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="char" char="." valign="bottom">14/DV4</td><td align="left" valign="bottom">CAMRDIGFGNVLHC</td><td align="char" char="." valign="bottom">35</td><td align="left" valign="bottom">WNRKRISNCVADYSV<sub>353–367</sub></td><td align="left" valign="bottom">DRA-DRB4*01:03</td></tr><tr><td align="left" valign="bottom" rowspan="7">#4</td><td align="left" valign="bottom">Post_2</td><td align="left" valign="bottom">25–1</td><td align="left" valign="bottom">CASTGDNYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">CAINTGNQFYF</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">YYVGYLQPR<sub>265–273</sub></td><td align="left" valign="bottom">A*33:03</td></tr><tr><td align="left" valign="bottom">Post_10</td><td align="left" valign="bottom">7–9</td><td align="left" valign="bottom">CASRPSGTSREQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">29</td><td align="left" valign="bottom">CAGNNAGNMLTF</td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom">FIKQYGDCLGDIAAR<sub>833–847</sub></td><td align="left" valign="bottom">A*33:03</td></tr><tr><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">7–9</td><td align="left" valign="bottom">CASSTRTSGGGLSYEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">CAVNKAAGNKLTF</td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">YSVLYNSASFSTFKC<sub>365–379</sub></td><td align="left" valign="bottom">A*24:02</td></tr><tr><td align="left" valign="bottom">Post_13</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSASIEQGDLGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">23/DV6</td><td align="left" valign="bottom">CAASIPNSGYALNF</td><td align="char" char="." valign="bottom">41</td><td align="left" valign="bottom">FIKQYGDCLGDIAAR<sub>833–847</sub></td><td align="left" valign="bottom">DQA1*01:02-DQB1*05:03</td></tr><tr><td align="left" valign="bottom">Post_14</td><td align="left" valign="bottom">5–6</td><td align="left" valign="bottom">CASSPGQGILEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">24</td><td align="left" valign="bottom">CAFVPLSDGQKLLF</td><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom">YIKWPWYIWL<sub>1209–1218</sub></td><td align="left" valign="bottom">A*24:02</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">7–3</td><td align="left" valign="bottom">CASGIHTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="ndash" valign="bottom">26–1</td><td align="left" valign="bottom">CIVNNAGNMLTF</td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom">TDNTFVSGNCDVVIG<sub>1117–1131</sub></td><td align="left" valign="bottom">DQA1*01:02-DQB1*06:04</td></tr><tr><td align="left" valign="bottom">Post_16</td><td align="left" valign="bottom">7–6</td><td align="left" valign="bottom">CASSPGPSEADTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="left" valign="bottom">CAVRDGDDKIIF</td><td align="char" char="." valign="bottom">30</td><td align="left" valign="bottom">KSTNLVKNKCVNFNF<sub>529–543</sub></td><td align="left" valign="bottom">DRA-DRB3*03:01</td></tr><tr><td align="left" valign="bottom" rowspan="3">#13</td><td align="left" valign="bottom">Post_13</td><td align="left" valign="bottom">7–2</td><td align="left" valign="bottom">CASSVGQSKGKSAETQYF</td><td align="char" char="ndash" valign="bottom">2–5</td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">CAVNEYSGAGSYQLTF</td><td align="char" char="." valign="bottom">28</td><td align="left" valign="bottom">SKRSFIEDLLFNKVT<sub>813–827</sub></td><td align="left" valign="bottom">DPA1*01:03-DPB1*02:01</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSAGDTASTYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALSDGAGNKLTF</td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">NQFNSAIGKIQ<sub>925–935</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td></tr><tr><td align="left" valign="bottom">Post_16</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">CAWSLQGQRPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="ndash" valign="bottom">38–1</td><td align="left" valign="bottom">CAFMKQRGGSEKLVF</td><td align="char" char="." valign="bottom">57</td><td align="left" valign="bottom">FIEDLLFNKVTLADA<sub>817–831</sub></td><td align="left" valign="bottom">DPA1*01:03-DPB1*02:01</td></tr><tr><td align="left" valign="bottom" rowspan="9">#15</td><td align="left" valign="bottom">Post_1</td><td align="left" valign="bottom">12–4</td><td align="left" valign="bottom">CASSSHRDRGVEAFF</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="char" char="ndash" valign="bottom">12–1</td><td align="left" valign="bottom">CVVNFDRGSTLGRLYF</td><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">TRGVYYPDKVF<sub>33–43</sub></td><td align="left" valign="bottom">B*15:01</td></tr><tr><td align="left" valign="bottom">Post_6</td><td align="left" valign="bottom">3–1</td><td align="left" valign="bottom">CASSQQLNTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="ndash" valign="bottom">38–2/DV8</td><td align="left" valign="bottom">CAYRKTSGTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">WRVYSTGSNVF<sub>633–643</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td></tr><tr><td align="left" valign="bottom">Post_7</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">CASSFPDRYYSNQPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="left" valign="bottom">CAVRAVGGNKLVF</td><td align="char" char="." valign="bottom">47</td><td align="left" valign="bottom">TRGVYYPDKVF<sub>33–43</sub></td><td align="left" valign="bottom">B*15:01</td></tr><tr><td align="left" valign="bottom">Post_9</td><td align="left" valign="bottom">27</td><td align="left" valign="bottom">CASSPGHEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">14/DV4</td><td align="left" valign="bottom">CAMSPIRTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">RSVASQSIIAY<sub>685–695</sub></td><td align="left" valign="bottom">B*15:01</td></tr><tr><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">3–1</td><td align="left" valign="bottom">CASSRELISEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="ndash" valign="bottom">38–2/DV8</td><td align="left" valign="bottom">CAYKRTSGTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">WRVYSTGSNVF<sub>633–643</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td></tr><tr><td align="left" valign="bottom">Post_12</td><td align="left" valign="bottom">28</td><td align="left" valign="bottom">CASSSYGTSGGRAEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom">CALSGGLTGGGNKLTF</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">LGDIAARDLICAQKF<sub>841–855</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td></tr><tr><td align="left" valign="bottom">Post_13</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">CAWRTGQGITSPLHF</td><td align="char" char="ndash" valign="bottom">1–6</td><td align="char" char="ndash" valign="bottom">8–2</td><td align="left" valign="bottom">CVVNNAGNMLTF</td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom">VFKNIDGYFKIYSKH<sub>193–207</sub></td><td align="left" valign="bottom">DPA1*02:02-DPB1*05:01</td></tr><tr><td align="left" valign="bottom">Post_14</td><td align="left" valign="bottom">6–1</td><td align="left" valign="bottom">CASSEAGGSGANVLTF</td><td align="char" char="ndash" valign="bottom">2–6</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALSGTGTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">KKFLPFQQFGR<sub>557–567</sub></td><td align="left" valign="bottom">DPA1*02:02-DPB1*05:01</td></tr><tr><td align="left" valign="bottom">Post_16</td><td align="left" valign="bottom">27</td><td align="left" valign="bottom">CASSLGTINTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">CATAPAGGTSYGKLTF</td><td align="char" char="." valign="bottom">52</td><td align="left" valign="bottom">IDGYFKIYSKHTPIN<sub>197–211</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td></tr><tr><td align="left" valign="bottom" rowspan="4">#17</td><td align="left" valign="bottom">Post_4</td><td align="left" valign="bottom">6–2</td><td align="left" valign="bottom">CASTSTARGSYNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="." valign="bottom">27</td><td align="left" valign="bottom">CAGHSNTGNQFYF</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">TRFASVYAWNRKRIS<sub>345–359</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td></tr><tr><td align="left" valign="bottom">Post_10</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">CASSKTSGAYNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALDNARLMF</td><td align="char" char="." valign="bottom">31</td><td align="left" valign="bottom">FIKQYGD<sub>833–839</sub></td><td align="left" valign="bottom">DRA-DRB1*15:01</td></tr><tr><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">20–1</td><td align="left" valign="bottom">CSARPPGGGNNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">26–2</td><td align="left" valign="bottom">CILRDGTGANNLFF</td><td align="char" char="." valign="bottom">36</td><td align="left" valign="bottom">QALNTLVKQLSSNFG<sub>957–971</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td></tr><tr><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">7–9</td><td align="left" valign="bottom">CASSLARGNSPLHF</td><td align="char" char="ndash" valign="bottom">1–6</td><td align="char" char="ndash" valign="bottom">38–2/DV8</td><td align="left" valign="bottom">CAFVGSQGNLIF</td><td align="char" char="." valign="bottom">42</td><td align="left" valign="bottom">AARDLICAQKFNGLT<sub>845–859</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><label>*</label><p>Overlapped epitope sequence is shown when a clonotype recognized two or three sequential peptides.</p></fn><fn id="table4fn2"><label>†</label><p>Number ranges indicate the location of peptides in the proteins.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Reactivity of each clonotype to mutated epitopes in SARS-CoV-2 VOCs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Donor</th><th align="left" valign="bottom">Clonotype</th><th align="left" valign="bottom" colspan="2">Mutated epitopes in VOCs</th><th align="left" valign="bottom">Domain</th><th align="left" valign="bottom">Response</th></tr></thead><tbody><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Post_4</td><td align="left" valign="bottom">Omicron BA.1<break/>Omicron BA.2, 4/5</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">P</styled-content>F<styled-content style="color: #D50000;">F</styled-content>TFKCYGVSPTKL<xref ref-type="table-fn" rid="table5fn1">*</xref><break/><styled-content style="color: #D50000;">P</styled-content>F<styled-content style="color: #D50000;">FA</styled-content>FKCYGVSPTKL</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓<break/>↓</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Post_5</td><td align="left" valign="bottom">Omicron BA.1</td><td align="left" valign="bottom">FKIYSKHTPI<styled-content style="color: #D50000;">I</styled-content></td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↑</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Post_6</td><td align="left" valign="bottom">Delta, Omicron BA.2, 4/5<break/>Omicron BA.1</td><td align="left" valign="bottom">FQFCNDPFL<styled-content style="color: #D50000;">D</styled-content>VYYHK<break/>FQFCNDPFL<styled-content style="color: #D50000;">D---</styled-content>HK</td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↓<break/>↓</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Post_7</td><td align="left" valign="bottom">Omicron BA.1<break/>Omicron BA.2, 4/5</td><td align="left" valign="bottom">YSVLYN<styled-content style="color: #D50000;">L</styled-content>A<styled-content style="color: #D50000;">P</styled-content>F<styled-content style="color: #D50000;">F</styled-content>TFKC<break/>YSVLYN<styled-content style="color: #D50000;">F</styled-content>A<styled-content style="color: #D50000;">P</styled-content>F<styled-content style="color: #D50000;">FA</styled-content>FKC</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓<break/>↓</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Post_8</td><td align="left" valign="bottom">Omicron BA1, 2, 4/5</td><td align="left" valign="bottom">LLQYGSFCTQL<styled-content style="color: #D50000;">K</styled-content>RAL</td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↑</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Post_10</td><td align="left" valign="bottom">Omicron BA1, 2, 4/5</td><td align="left" valign="bottom">LLQYGSFCTQL<styled-content style="color: #D50000;">K</styled-content>RAL</td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↑</td></tr><tr><td align="left" valign="bottom">#27</td><td align="left" valign="bottom">Post_5</td><td align="left" valign="bottom">Delta<break/>Omicron BA.1, 2, 4/5</td><td align="left" valign="bottom">STEIYQAGS<styled-content style="color: #D50000;">K</styled-content>PCNGV<break/>STEIYQAG<styled-content style="color: #D50000;">NK</styled-content>PCNGV</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓<break/>↓</td></tr><tr><td align="left" valign="bottom">#27</td><td align="left" valign="bottom">Post_13</td><td align="left" valign="bottom">Delta<break/>Omicron BA.1, 2, 4/5</td><td align="left" valign="bottom">STEIYQAGS<styled-content style="color: #D50000;">K</styled-content>PCNGV<break/>STEIYQAG<styled-content style="color: #D50000;">NK</styled-content>PCNGV</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓<break/>↓</td></tr><tr><td align="left" valign="bottom">#28</td><td align="left" valign="bottom">Post_5</td><td align="left" valign="bottom">Omicron BA.1</td><td align="left" valign="bottom">LVKNKCVNFNFNGL<styled-content style="color: #D50000;">K</styled-content></td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↑</td></tr><tr><td align="left" valign="bottom">#28</td><td align="left" valign="bottom">Post_10</td><td align="left" valign="bottom">Omicron BA.2, 4/5</td><td align="left" valign="bottom">VIRG<styled-content style="color: #D50000;">N</styled-content>EV<styled-content style="color: #D50000;">S</styled-content>QIA</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓</td></tr><tr><td align="left" valign="bottom">#28</td><td align="left" valign="bottom">Post_14</td><td align="left" valign="bottom">Omicron BA.1, 2, 4/5</td><td align="left" valign="bottom">PF<styled-content style="color: #D50000;">D</styled-content>EVFNATRFASVY</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓</td></tr><tr><td align="left" valign="bottom">#4</td><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">Omicron BA.1<break/>Omicron BA.2, 4/5</td><td align="left" valign="bottom">YSVLYN<styled-content style="color: #D50000;">L</styled-content>A<styled-content style="color: #D50000;">P</styled-content>F<styled-content style="color: #D50000;">F</styled-content>TFKC<break/>YSVLYN<styled-content style="color: #D50000;">F</styled-content>A<styled-content style="color: #D50000;">P</styled-content>F<styled-content style="color: #D50000;">FA</styled-content>FKC</td><td align="left" valign="bottom">RBD</td><td align="left" valign="bottom">↓<break/>↓</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Post_9</td><td align="left" valign="bottom">Delta<break/>Omicron BA.1, 2, 4/5</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">R</styled-content>RRARSVASQSIIAY<break/><styled-content style="color: #D50000;">H</styled-content>RRARSVASQSIIAY</td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↑<break/>↑</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Post_16</td><td align="left" valign="bottom">Omicron BA.1</td><td align="left" valign="bottom">IDGYFKIYSKHTPI<styled-content style="color: #D50000;">I</styled-content></td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">→</td></tr><tr><td align="left" valign="bottom">#17</td><td align="left" valign="bottom">Post_11</td><td align="left" valign="bottom">Omicron BA.1, 2, 4/5</td><td align="left" valign="bottom">QALNTLVKQLSS<styled-content style="color: #D50000;">K</styled-content>FG</td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↓</td></tr><tr><td align="left" valign="bottom">#17</td><td align="left" valign="bottom">Post_15</td><td align="left" valign="bottom">Omicron BA.1</td><td align="left" valign="bottom">AARDLICAQKF<styled-content style="color: #D50000;">K</styled-content>GLT</td><td align="left" valign="bottom">non-RBD</td><td align="left" valign="bottom">↓</td></tr></tbody></table><table-wrap-foot><fn id="table5fn1"><label>*</label><p>Amino acids colored red indicate mismatches compared with corresponding S epitopes of Wuhan strain.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Identification of S epitopes and cross-reactive antigens of pre-existing T cell clonotypes</title><p>Before the pandemic, T cells cross-reacting to S antigen were present in the peripheral blood (<xref ref-type="bibr" rid="bib14">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Mateus et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Sekine et al., 2020</xref>). To characterize these pre-existing S-reactive cells, we analyzed the PBMCs collected from donors who consented to blood sample donation before vaccination (#4, #8, #13, #15, and #17). PBMCs were stimulated with the S peptide pool for 10 days, and proliferated T cells were sorted and analyzed by scTCR/RNA-seq. Similar to vaccine-induced S-reactive T cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), characteristics of pre-existing S-reactive T cells were diverse (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="scode1">Source code 1</xref>). To track the dynamics of cross-reactive clones after vaccination, we combined the single-cell sequencing data of pre- and post-vaccinated PBMCs and analyzed the clonotypes that have more than 50 cells in total (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We did find some cross-reactive clonotypes that were further expanded by vaccination, and most of these clonotypes had cytotoxic features, being CD8<sup>+</sup> effector memory T cells (Tem) or minor CD4<sup>+</sup> cytotoxic T cells (CTLs). In contrast, most of the cross-reactive CD4<sup>+</sup> T cells became minor clonotypes after vaccination.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Characteristics and dynamics of S-cross-reactive clonotypes.</title><p>(<bold>A</bold>) UMAP projection of T cells in single-cell analysis of pre-vaccinated samples from donors #4, #13, #15, #17, and #8. Each dot corresponds to a single cell and is colored according to the samples from different donors. Annotated cell types are shown. (<bold>B</bold>) Donor, name of reconstituted clonotypes, cell type, clonotype fraction in T cells from each time points, and expansion ratio of clonotypes that were found in pre-vaccinated samples and had more than 50 cells in the combined pre- and post-vaccinated sample set. For clonotypes that showed more than one type, the major type is listed in the front. The expansion ratio was calculated using the maximum cell fraction at post-vaccination points divided by the cell fraction at the pre-vaccination point of each clonotype. Clonotypes that have an expansion ratio larger than 1 are considered as expanded post-vaccination. Cell fractions at individual time points are shown as heat map. Tfr, follicular regulatory T cells; MAIT, mucosal-associated invariant T cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig4-v1.tif"/></fig><p>We also explored the epitopes of the top 16 expanded clonotypes in each pre-vaccinated donor by reconstituting the TCRs into reporter cell lines. We identified 18 epitopes from S protein and determined some possible cross-reactive antigens (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="table" rid="table6">Table 6</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Most of these cross-reactive antigens originated from environmental or symbiotic microbes (<xref ref-type="table" rid="table6">Table 6</xref>). Furthermore, majority of the reactive T clonotypes showed regulatory T cell (Treg) signatures (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Six of these 80 analyzed clonotypes could also be frequently detected in the public TCR database Adaptive (<xref ref-type="bibr" rid="bib11">Emerson et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Nolan et al., 2020</xref>). Notably, most of these clonotypes, except for one case, showed comparable frequencies between pre-pandemic healthy donors and COVID-19 patients (<xref ref-type="fig" rid="fig6">Figure 6</xref>), suggesting that these clonotypes did not expand upon SARS-CoV-2 infection, despite they were present before the pandemic. Thus, it is unlikely that these cross-reactive T clonotypes contribute to the establishment of S-reactive T cell pools during either vaccination or infection.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The location of S epitopes of pre-existing S-reactive T cells.</title><p>S epitopes recognized by top expanded TCR clonotypes in pre-vaccinated samples are mapped by their locations in S protein. Each short bar indicates a 15-mer peptide that activated the TCRs. Epitopes are shown in different colors according to the subtypes of the T cells they activated. Relative frequencies of the T cell subtypes from all five donors are shown in the pie chart. Numbers of identified epitopes recognized by a dominant T subset of pre-existing clonotypes (Treg) from all donors are shown in green bars.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Determination of S epitopes, restricting HLAs and cross-reactive epitopes for pre-existing T cell clonotypes expanded by S stimulation.</title><p>Reporter cells expressing TCRs were stimulated with 1 µg/ml of indicated S peptides in the presence of transformed B cells or HEK293T cells expressing indicated HLAs for overnight, and analyzed for GFP and CD69 expression. (<bold>A</bold>) Determination of S epitopes of T cell clonotypes. (<bold>B</bold>) Determination of restricting HLAs of T cell clonotypes. (<bold>C</bold>) Determination of cross-reactive epitopes of T cell clonotypes. Sequences of cross-reactive peptides are in <xref ref-type="table" rid="table6">Table 6</xref>. Data are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>The pre-existing S-reactive T cell clonotypes did not recognize HCoV epitopes.</title><p>The only two clonotypes whose epitope sequences were relatively conserved in HCoV strains, donor #8-pre_9 and pre_10, were tested for their reactivity to the similar HCoV epitope counterparts. Reporter cell lines of these clonotypes were co-cultured with indicated peptides as well as APCs, and analyzed for GFP and CD69 expression. Data are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig5-figsupp2-v1.tif"/></fig></fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Frequencies of pre-existing S-reactive clonotypes in the public database of uninfected and infected cohorts.</title><p>TCRβ sequences of the top expanded clonotypes in pre-vaccinated samples were investigated in the Adaptive database. Frequencies of detected clonotypes are shown in box plot. Healthy, dataset from 786 healthy donors. COVID, dataset from 1485 COVID-19 patients.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89999-fig6-v1.tif"/></fig><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>S-coss-reactive TCR clonotypes expanded in pre-vaccinated samples and their TCR usages, epitopes, restricting HLAs and cross-reactive epitopes in microbes other than SARS-CoV-2.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Donor</th><th align="left" valign="bottom">Clonotype</th><th align="left" valign="bottom">TRBV</th><th align="left" valign="bottom">CDR3β</th><th align="left" valign="bottom">TRBJ</th><th align="left" valign="bottom">TRAV</th><th align="left" valign="bottom">CDR3α</th><th align="left" valign="bottom">TRAJ</th><th align="left" valign="bottom">S epitope</th><th align="left" valign="bottom">Restricting HLA</th><th align="left" valign="bottom">Cross-reactive antigen [species]</th><th align="left" valign="bottom">Cross-reactive peptide</th><th align="left" valign="bottom">Post-vaccinated expansion</th></tr></thead><tbody><tr><td align="left" valign="bottom">#4</td><td align="left" valign="bottom">Pre_5</td><td align="char" char="ndash" valign="bottom">6–6</td><td align="left" valign="bottom">CASSYPGGGGSETQYF</td><td align="char" char="ndash" valign="bottom">2–5</td><td align="char" char="." valign="bottom">35</td><td align="left" valign="bottom">CAGVAVQGAQKLVF</td><td align="char" char="." valign="bottom">54</td><td align="left" valign="bottom">LLALHRSY<break/>LTP<sub>241–251</sub><xref ref-type="table-fn" rid="table6fn1">*</xref></td><td align="left" valign="bottom">DRA-DRB1*14:54</td><td align="left" valign="bottom">Phosphoribosyl<break/>formylglycinamidine <break/>cyclo-ligase <break/>[<italic>Firmicutes bacterium</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">VAEA</styled-content>LLA<styled-content style="color: #D50000;">V</styled-content>HR<break/>SYLTP<sub>220-234</sub><xref ref-type="table-fn" rid="table6fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#4</td><td align="left" valign="bottom">Pre_7</td><td align="char" char="ndash" valign="bottom">6–6</td><td align="left" valign="bottom">CASSYPGGSGGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">CAVENSGNTPLVF</td><td align="char" char="." valign="bottom">29</td><td align="left" valign="bottom">LLALHRSY<break/>LTP<sub>241–251</sub></td><td align="left" valign="bottom">DQA1*01:04-DQB1*05:03</td><td align="left" valign="bottom">Phosphoribosylf<break/>ormylglycinamidine <break/>cyclo-ligase <break/>[<italic>Firmicutes bacterium</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">VAEA</styled-content>LLA<styled-content style="color: #D50000;">V</styled-content>HR<break/>SYLTP<sub>220-234</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_1</td><td align="char" char="ndash" valign="bottom">6–2</td><td align="left" valign="bottom">CASRPNRGRFRGNQPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="." valign="bottom">23/DV6</td><td align="left" valign="bottom">CAGEEKETSGSRLTF</td><td align="char" char="." valign="bottom">58</td><td align="left" valign="bottom">NCTFEYVSQP<break/>FLMDL<sub>165–179</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td><td align="left" valign="bottom">Fumarylacetoacetate <break/>hydrolase family protein <break/>[<italic>Alcaligenes faecalis</italic>]<break/>Hypothetical protein <break/>[<italic>Planctomycetales bacterium</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">ASLI</styled-content>EYVSQP<break/>FL<styled-content style="color: #D50000;">LEP</styled-content><sub>225-239</sub><break/><styled-content style="color: #D50000;">AAG</styled-content>FEYVSQ<break/>PF<styled-content style="color: #D50000;">SLP</styled-content>L<sub>533-547</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_2</td><td align="char" char="ndash" valign="bottom">6–1</td><td align="left" valign="bottom">CASIRDRVADTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="." valign="bottom">30</td><td align="left" valign="bottom">CGTETTDSWGKLQF</td><td align="char" char="." valign="bottom">24</td><td align="left" valign="bottom">RFNGIGVTQ<break/>NV<sub>905–915</sub></td><td align="left" valign="bottom">DQA1*03:02-DQB1*03:03</td><td style="background-color: #E6E6E6;">SEL1-like repeat protein [<italic>Bacteroidaceae bacterium</italic>] <xref ref-type="table-fn" rid="table6fn3"><sup>‡</sup></xref></td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">LGV</styled-content>Y<styled-content style="color: #D50000;">Y</styled-content>FNGI<break/>GVTQ<styled-content style="color: #D50000;">DQ</styled-content><sub>236-250</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_3</td><td align="char" char="." valign="bottom">27</td><td align="left" valign="bottom">CATKGEANYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="ndash" valign="bottom">12–3</td><td align="left" valign="bottom">CAMSEMGTGFQKLVF</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">SIVRFPNI<break/>TNL<sub>325–335</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td><td style="background-color: #E6E6E6;">LTA synthase family protein [<italic>Dechloromonas denitrificans</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">L</styled-content>P<styled-content style="color: #D50000;">GK</styled-content>S<styled-content style="color: #D50000;">V</styled-content>VR<break/><styled-content style="color: #D50000;">W</styled-content>PNITNL<sub>330-344</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_5</td><td align="char" char="ndash" valign="bottom">5–1</td><td align="left" valign="bottom">CASSLRTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="ndash" valign="bottom">8–1</td><td align="left" valign="bottom">CAVNGRNTGFQKLVF</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">NFTISVTTEI<break/>LPVSM<sub>717–731</sub></td><td align="left" valign="bottom">DRA-DRB1*09:01</td><td align="left" valign="bottom">Major capsid protein <break/>[<italic>Human papillomavirus 145</italic>] <break/>Periplasmic trehalase <break/>[<italic>Chlamydiia bacterium</italic>]</td><td align="left" valign="bottom">NFTISVTT<styled-content style="color: #D50000;">DA</styled-content><break/><styled-content style="color: #D50000;">GDINE</styled-content><sub>350-364</sub><break/><styled-content style="color: #D50000;">LSTI</styled-content>VTTEIL<break/>PV<styled-content style="color: #D50000;">DL</styled-content><sub>288-301</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_9</td><td align="char" char="ndash" valign="bottom">7–2</td><td align="left" valign="bottom">CASAAGGTGGETQYF</td><td align="char" char="ndash" valign="bottom">2–5</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CAETPFLSGTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">YIKWPWYIW<break/>LGFIAG<sub>1209–1223</sub></td><td align="left" valign="bottom">DRA-DRB5*01:02</td><td style="background-color: #E6E6E6;">Spike glycoprotein <break/>[<italic>Human coronavirus HKU1</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">V</styled-content>KWPWY<styled-content style="color: #D50000;">V</styled-content><break/>WL<styled-content style="color: #D50000;">LISFSF</styled-content><sub>1297-1311</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_10</td><td align="char" char="ndash" valign="bottom">6–6</td><td align="left" valign="bottom">CASSLGQGIHEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="ndash" valign="bottom">26–1</td><td align="left" valign="bottom">CIVERGGSNYKLTF</td><td align="char" char="." valign="bottom">53</td><td align="left" valign="bottom">SKRSFIEDL<break/>LFNKVT<sub>813–827</sub></td><td align="left" valign="bottom">DPA1*01:03-DPB1*04:02</td><td align="left" valign="bottom">Hypothetical protein, partial <break/>[<italic>Acinetobacter baumannii</italic>] <break/>Spike protein <break/>[<italic>Feline coronavirus</italic>] <break/>Spike protein <break/>[<italic>Canine coronavirus</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">G</styled-content>KRS<styled-content style="color: #D50000;">AV</styled-content>EDL<break/>LFNKV<styled-content style="color: #D50000;">V</styled-content><sub>204-218</sub> <styled-content style="color: #D50000;">G</styled-content>KRS<styled-content style="color: #D50000;">AV</styled-content>EDL<break/>LFNKV<styled-content style="color: #D50000;">V</styled-content><sub>980-994</sub> <styled-content style="color: #D50000;">G</styled-content>KRS<styled-content style="color: #D50000;">AV</styled-content>EDLL<break/>FNKV<styled-content style="color: #D50000;">V</styled-content><sub>977-991</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_14</td><td align="char" char="ndash" valign="bottom">4–3</td><td align="left" valign="bottom">CASSQRQGAGDTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">CALSEAGIQGAQKLVF</td><td align="char" char="." valign="bottom">54</td><td align="left" valign="bottom">IDRLITGRLQ<break/>SLQTY<sub>993–1007</sub></td><td align="left" valign="bottom">DQA1*01:03-DQB1*06:01</td><td style="background-color: #E6E6E6;">Excinuclease ABC subunit UvrA [<italic>Lentisphaeria bacterium</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">V</styled-content>DRLITGRL<styled-content style="color: #D50000;">E</styled-content><break/>S<styled-content style="color: #D50000;">SRLN</styled-content><sub>208-222</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#8</td><td align="left" valign="bottom">Pre_15</td><td align="char" char="ndash" valign="bottom">20–1</td><td align="left" valign="bottom">CSAKDRIYGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="ndash" valign="bottom">26–1</td><td align="left" valign="bottom">CIVRSPSGSARQLTF</td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">MIAQYTSAL<break/>LA<sub>869–879</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td><td align="left" valign="bottom">MATE family efflux transporter [<italic>Selenomonas noxia</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">ATI</styled-content>IAQYTSA<break/>LLA<styled-content style="color: #D50000;">LR</styled-content><sub>242-256</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#13</td><td align="left" valign="bottom">Pre_5</td><td align="char" char="ndash" valign="bottom">4–3</td><td align="left" valign="bottom">CASSQVSTGTGITGANVLTF</td><td align="char" char="ndash" valign="bottom">2–6</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CARRSSSASKIIF</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">QNVLYENQ<break/>KLI<sub>913–923</sub></td><td align="left" valign="bottom">DRA-DRB5*01:01</td><td align="left" valign="bottom">Hypothetical protein <break/>[<italic>Neobacillus vireti</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">T</styled-content>NVLYENQKL<break/><styled-content style="color: #D50000;">FL</styled-content>N<styled-content style="color: #D50000;">L</styled-content>F<sub>169-183</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#13</td><td align="left" valign="bottom">Pre_8</td><td align="char" char="." valign="bottom">18</td><td align="left" valign="bottom">CASSPRAPPYEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom">CAVRPAGGTGNQFYF</td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom">DKYFKNHTSP<break/>DVDLG<sub>1153–1167</sub></td><td align="left" valign="bottom">DRA-DRB1*15:01</td><td style="background-color: #E6E6E6;">Type VI secretion <break/>system contractile <break/>sheath large subunit <break/>[<italic>Salmonella enterica</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">D</styled-content>Y<styled-content style="color: #D50000;">YFD</styled-content>HTSP<break/>DVDL<styled-content style="color: #D50000;">LG</styled-content><sub>167-181</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#13</td><td align="left" valign="bottom">Pre_12</td><td align="char" char="ndash" valign="bottom">4–2</td><td align="left" valign="bottom">CASSQEGNTEAFF</td><td align="char" char="ndash" valign="bottom">1–1</td><td align="char" char="." valign="bottom">20</td><td align="left" valign="bottom">CGCRGGTSYGKLTF</td><td align="char" char="." valign="bottom">52</td><td align="left" valign="bottom">NVTWFHAIH<break/>VSGTNG<sub>61–75</sub></td><td align="left" valign="bottom">DQA1*01:02-DQB1*06:02</td><td style="background-color: #E6E6E6;">Dihydrofolate synthase <break/>[<italic>Actinobaculum sp. 313</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">PQRS</styled-content>FHAIH<break/>V<styled-content style="color: #D50000;">T</styled-content>GTNG<sub>61-75</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_1</td><td align="char" char="ndash" valign="bottom">20–1</td><td align="left" valign="bottom">CSARDLTASAHGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom">CATDAGQGGKLIF</td><td align="char" char="." valign="bottom">23</td><td align="left" valign="bottom">SVTTEILP<break/>VSM<sub>721–731</sub></td><td align="left" valign="bottom">DQA1*01:03-DQB1*06:01</td><td align="left" valign="bottom">Hypothetical protein <break/>[<italic>Myxococcales bacterium</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">P</styled-content>VTTEILPVS<styled-content style="color: #D50000;">D</styled-content><break/><styled-content style="color: #D50000;">DPPG</styled-content><sub>525-539</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_2</td><td align="char" char="ndash" valign="bottom">24–1</td><td align="left" valign="bottom">CATSDLDQPQHF</td><td align="char" char="ndash" valign="bottom">1–5</td><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom">CALSGYGSGYSTLTF</td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">SVTTEILP<break/>VSM<sub>721–731</sub></td><td align="left" valign="bottom">DQA1*01:03-DQB1*06:01</td><td align="left" valign="bottom">Hypothetical protein <break/>[<italic>Myxococcales bacterium</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">P</styled-content>VTTEILPVS<break/><styled-content style="color: #D50000;">DDPPG</styled-content><sub>525-539</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_3</td><td align="char" char="ndash" valign="bottom">6–1</td><td align="left" valign="bottom">CASDPKNGGEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">29/DV5</td><td align="left" valign="bottom">CAASVGFGNVLHC</td><td align="char" char="." valign="bottom">35</td><td align="left" valign="bottom">FKIYSKH<break/>TPIN<sub>201–211</sub></td><td align="left" valign="bottom">DRA-DRB5*01:02</td><td align="left" valign="bottom">Uncharacterized protein <break/>APUU_31,289 S <break/>[<italic>Aspergillus puulaauensis</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">CRAA</styled-content>FKLY<break/>SKHTP<styled-content style="color: #D50000;">VE</styled-content><sub>123-137</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_4</td><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom">CASGLAGGNTGELFF</td><td align="char" char="ndash" valign="bottom">2–2</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">CVPSSGGYNKLIF</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">QALNTLVK<break/>QLS<sub>957–967</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td><td style="background-color: #E6E6E6;">4-hydroxybenzoate octaprenyltransferase <break/>[<italic>Pseudoduganella dura</italic>]</td><td style="background-color: #E6E6E6;">IQ<styled-content style="color: #D50000;">P</styled-content>LNTLVKQ<break/>LS<styled-content style="color: #D50000;">VAA</styled-content><sub>112-126</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_5</td><td align="char" char="ndash" valign="bottom">6–5</td><td align="left" valign="bottom">CASSAGLAGGGNTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">CAVISGSARQLTF</td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">QALNTLV<break/>KQLS<sub>957–967</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td><td style="background-color: #E6E6E6;">4-hydroxybenzoate octaprenyltransferase <break/>[<italic>Pseudoduganella dura</italic>]</td><td style="background-color: #E6E6E6;">IQ<styled-content style="color: #D50000;">P</styled-content>LNTLVKQ<break/>LS<styled-content style="color: #D50000;">VAA</styled-content><sub>112-126</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_6</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">CASVGGNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALTRFVGGATNKLIF</td><td align="char" char="." valign="bottom">32</td><td align="left" valign="bottom">RTFLLKYN<break/>ENGTITD<sub>273–287</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td><td align="left" valign="bottom">Unnamed protein product <break/>[<italic>Mytilus edulis</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">NKK</styled-content>LLKYNE<break/>NGT<styled-content style="color: #D50000;">F</styled-content>IT<sub>277-291</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_7</td><td align="char" char="ndash" valign="bottom">4–1</td><td align="left" valign="bottom">CASSHDGTPPDTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="." valign="bottom">29/DV5</td><td align="left" valign="bottom">CAAYSNYQLIW</td><td align="char" char="." valign="bottom">33</td><td align="left" valign="bottom">FKIYSKHT<break/>PIN<sub>201–211</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td><td align="left" valign="bottom">Uncharacterized protein <break/>APUU_31,289 S <break/>[<italic>Aspergillus puulaauensis</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">CRAA</styled-content>FKLYS<break/>KHTP<styled-content style="color: #D50000;">VE</styled-content><sub>123-137</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#15</td><td align="left" valign="bottom">Pre_15</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">CASSETGRGTDTQYF</td><td align="char" char="ndash" valign="bottom">2–3</td><td align="char" char="ndash" valign="bottom">9–2</td><td align="left" valign="bottom">CALYRGTYKYIF</td><td align="char" char="." valign="bottom">40</td><td align="left" valign="bottom">LQSLQTYV<break/>TQQLIRA<sub>1001–1015</sub></td><td align="left" valign="bottom">DRA-DRB1*15:02</td><td align="left" valign="bottom">Dyp-type peroxidase <break/>[<italic>Acinetobacter sp</italic>.]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">CTV</styled-content>LQTYVTQ<break/>QL<styled-content style="color: #D50000;">ESV</styled-content><sub>134-148</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#17</td><td align="left" valign="bottom">Pre_7</td><td align="char" char="ndash" valign="bottom">6–1</td><td align="left" valign="bottom">CASSLRGAFGYTF</td><td align="char" char="ndash" valign="bottom">1–2</td><td align="char" char="." valign="bottom">35</td><td align="left" valign="bottom">CAGHLYGGSQGNLIF</td><td align="char" char="." valign="bottom">42</td><td align="left" valign="bottom">NCTFEYVSQP<break/>FLMDL<sub>165–179</sub></td><td align="left" valign="bottom">DPA1*01:03-DPB1*04:02</td><td align="left" valign="bottom">Fumarylacetoacetate <break/>hydrolase family protein <break/>[<italic>Alcaligenes faecalis</italic>]<break/>Hypothetical protein <break/>[<italic>Planctomycetales bacterium</italic>]</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">ASLI</styled-content>EYVSQP<break/>FL<styled-content style="color: #D50000;">LEP</styled-content><sub>225-239</sub> <break/><styled-content style="color: #D50000;">AAG</styled-content>FEYVSQ<break/>PF<styled-content style="color: #D50000;">SLP</styled-content>L<sub>533-547</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#17</td><td align="left" valign="bottom">Pre_8</td><td align="char" char="ndash" valign="bottom">5–1</td><td align="left" valign="bottom">CASSLNSGANVLTF</td><td align="char" char="ndash" valign="bottom">2–6</td><td align="char" char="ndash" valign="bottom">13–1</td><td align="left" valign="bottom">CAASIVQDQKLVF</td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom">LTPTWRVYS<break/>TGSNVF<sub>629–643</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td><td style="background-color: #E6E6E6;">Hypothetical protein <break/>[<italic>Novosphingobium chloroacetimidivorans</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">APG</styled-content>TPTWRV<break/>YST<styled-content style="color: #D50000;">ART</styled-content><sub>277-291</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#17</td><td align="left" valign="bottom">Pre_14</td><td align="char" char="ndash" valign="bottom">5–1</td><td align="left" valign="bottom">CASSLGAGLYNEQFF</td><td align="char" char="ndash" valign="bottom">2–1</td><td align="char" char="ndash" valign="bottom">38–1</td><td align="left" valign="bottom">CAFINNNAGNMLTF</td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom">QALNTLVK<break/>QLS<sub>957–967</sub></td><td align="left" valign="bottom">DRA-DRB1*08:02</td><td align="left" valign="bottom">4-hydroxybenzoate octaprenyltransferase <break/>[<italic>Pseudoduganella dura</italic>]</td><td align="left" valign="bottom">IQ<styled-content style="color: #D50000;">P</styled-content>LNTLVKQ<break/>LS<styled-content style="color: #D50000;">VAA</styled-content><sub>112-126</sub></td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">#17</td><td align="left" valign="bottom">Pre_15</td><td align="char" char="ndash" valign="bottom">7–2</td><td align="left" valign="bottom">CASSRTSGGTYEQYF</td><td align="char" char="ndash" valign="bottom">2–7</td><td align="char" char="." valign="bottom">25</td><td align="left" valign="bottom">CAGQNTDKLIF</td><td align="char" char="." valign="bottom">34</td><td align="left" valign="bottom">SIVRFPNI<break/>TNL<sub>325–335</sub></td><td align="left" valign="bottom">DRA-DRB1*15:01</td><td style="background-color: #E6E6E6;">LTA synthase family protein [<italic>Dechloromonas denitrificans</italic>]</td><td style="background-color: #E6E6E6;"><styled-content style="color: #D50000;">L</styled-content>P<styled-content style="color: #D50000;">GK</styled-content>S<styled-content style="color: #D50000;">V</styled-content>VR<break/><styled-content style="color: #D50000;">W</styled-content>PNITNL<sub>330-344</sub></td><td align="left" valign="bottom">Yes</td></tr></tbody></table><table-wrap-foot><fn id="table6fn1"><label>*</label><p>Number ranges indicate the location of peptides in the proteins.</p></fn><fn id="table6fn2"><label>†</label><p>Amino acids colored red indicate mismatches compared with corresponding S epitopes of Wuhan strain.</p></fn><fn id="table6fn3"><label>‡</label><p>Antigen names and peptide sequences in cells with gray background indicate inactive antigens of the corresponding T clonotypes.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Previous studies showed that Tfh function and germinal center development were impaired in deceased COVID-19 patients (<xref ref-type="bibr" rid="bib21">Kaneko et al., 2020</xref>) and Tfh cell number correlated with neutralizing antibody (<xref ref-type="bibr" rid="bib13">Gong et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Juno et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Zhang et al., 2021</xref>). Consistent with the above studies, we found that the donors having sustained antibody titers between 6 and 24 weeks post-vaccination had more S antigen-responsive Tfh-like clonotypes maintained in the periphery as a memory pool. As circulating Tfh clonotypes can reflect the population of germinal center Tfh cells (<xref ref-type="bibr" rid="bib7">Brenna et al., 2020</xref>), it is possible that these maintained S-responsive Tfh cells contribute to the prolonged production of anti-S antibodies. These results imply that Tfh polarization of S-reactive T cells in the blood after 2nd vaccination can be a marker for the longevity of serum anti-S antibodies. Although monitoring of S-specific Tfh cells in germinal center is ideal (<xref ref-type="bibr" rid="bib33">Mudd et al., 2022</xref>), it is currently difficult for outpatients in clinics.</p><p>Since the antigen used for BNT162b2 is a full-length S protein from the Wuhan-Hu-1 strain, it is important to estimate whether vaccine-induced Wuhan S-reactive T cells recognize neutralizing antibody-evading VOCs, such as Omicron variants. To investigate the dominant T cell epitopes of vaccine-developed T cells, we utilized a proliferation-based sorting strategy to enrich the S-responsive T cells. The limitation of this strategy is that a 10 day stimulation would change the transcriptional profile and repertoire of T cells. However, this strategy allowed us to select the T cell clonotypes that vigorously responded to the S antigen stimulation, while weakly responsive cells and anergic cells will be less considered, which is exactly in line with our purpose. Consistent with previous reports (<xref ref-type="bibr" rid="bib12">GeurtsvanKessel et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Keeton et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Tarke et al., 2022</xref>), most of the epitopes determined in the current study were conserved in Delta and Omicron (BA.1, BA.2, and BA.4/5) strains, suggesting that vaccine-induced T cells are able to recognize the mutated S proteins from these variants, despite the B epitopes being largely mutated in these VOCs (<xref ref-type="bibr" rid="bib12">GeurtsvanKessel et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Tarke et al., 2022</xref>).</p><p>SARS-CoV-2-recognizing T cells existed prior to exposure to the S antigens (<xref ref-type="bibr" rid="bib14">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Mateus et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Sekine et al., 2020</xref>), which is consistent with our observation with PBMCs from donors who were uninfected and pre-vaccinated. Among these pre-existing S-reactive clonotypes, CD8<sup>+</sup> cytotoxic T clonotypes were expanded by the vaccination, whereas most CD4<sup>+</sup> T clonotypes became less dominant after vaccination (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Currently, the reason for the opposite tendency is unclear. In the present study, we showed that pre-existing T clonotypes cross-reacting to S protein are unlikely to contribute to vaccine-driven T cell immunity. This could be due to the fact that cross-reactive T cells had relatively low avidity to S protein (<xref ref-type="bibr" rid="bib3">Bacher et al., 2020</xref>). Alternatively, but not mutually exclusively, considering that most of these cross-reactive T clonotypes have Treg signature (<xref ref-type="fig" rid="fig5">Figure 5</xref>), they could be developed to tolerate symbiotic or environmental antigens, and might be ineffective to the defense against SARS-CoV-2 and thus replaced by the other effective T clonotypes induced by vaccination. One exceptional pre-existing clonotype was #15-Pre_2, as they vigorously expanded in COVID-19 patients (<xref ref-type="fig" rid="fig6">Figure 6</xref>). This clonotype was clustered within a CD4<sup>+</sup> Tem population and cross-reactive to environmental bacteria, <italic>Myxococcales bacterium</italic> (<xref ref-type="table" rid="table6">Table 6</xref>). Thus, in some particular settings, clonotypes primed by common bacterial antigens might potentially contribute during infection.</p><p>Common cold human coronavirus (HCoV)-derived S proteins are reported as potential cross-reactive antigens for pre-existing SARS-CoV-2 S-reactive T cells (<xref ref-type="bibr" rid="bib6">Becerra-Artiles et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Low et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Loyal et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">Mateus et al., 2020</xref>). However, the highly responding SARS-CoV-2 S-reactive clonotypes in pre-vaccinated donors did not react with HCoV S proteins in the present study (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>), which might be partly due to the difference of cohorts or ethnicities. Instead, most of those T cells cross-reacted with environmental or symbiotic bacteria. These observations suggest that these cross-reactive T cells might have been developed to establish tolerance against less harmful microbes, and thus unlikely to efficiently contribute to the protective viral immunity. Vaccination may induce opposite tendencies on T cell clonotypes that recognize the same antigen (<xref ref-type="bibr" rid="bib2">Aoki et al., 2022</xref>), which is hardly detected by the bulk T cell analyses. The current study highlights the necessity of dynamic tracing of T cell responses in an epitope-specific clonotype resolution for the evaluation of vaccine-induced immunity.</p><p>The limitation of this study is the number of individuals we analyzed. However, chronological and clonological analysis of antigen-specific T cells in characteristic groups followed by epitope determination has not been performed before. This study suggests that mRNA vaccine is potent enough to prime rare T cell clonotypes that become dominant afterwards. Furthermore, we propose that the types of CD4<sup>+</sup> T clonotypes developed shortly after two doses of vaccination could be an indication of the longevity of antibodies in the following months. Tfh-inducing adjuvants or Tfh-skewing epitope would be a promising ‘directional’ booster in the post-vaccine era when most people worldwide were exposed to the same antigen in multiple doses within a short period. Furthermore, in addition to SARS-CoV-2, this strategy can also be applicable for the prevention of other infectious diseases of which neutralizing antibody titers are effective for protection.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Human IgG HRP (Goat polyclonal)</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">ab97175</td><td align="left" valign="top">ELISA (1:5000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-SARS-CoV-IgG WHO international Standard (Human polyclonal)</td><td align="left" valign="top">NIBSC</td><td align="char" char="." valign="top">20/136</td><td align="left" valign="top">ELISA (10–31250)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-human CD3-FITC (mouse monoclonal)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat#: 300305</td><td align="left" valign="top">FACS (1:100)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">TotalSeq-C anti-human Hashtags (mouse monoclonal, mixture)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat#: 394661, etc</td><td align="left" valign="top">Single-cell sequencing (1:50)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-mouse CD69-APC (armenian hamster monoclonal)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat#: 104513</td><td align="left" valign="top">FACS (1:100)</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">SARS-CoV-2 Spike (trimeric)</td><td align="left" valign="top">Cell Signaling Technology</td><td align="left" valign="top">#65444</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">SARS-CoV-2 Nucleocapsid protein</td><td align="left" valign="top">ACRO Biosystems</td><td align="left" valign="top">NUN-C5227</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">SARS-CoV-2 (Spike Glycoprotein), PepMix</td><td align="left" valign="top">JPT Peptide Technologies GmbH</td><td align="left" valign="top">JER-PM-WCPV-S-1–2</td><td align="left" valign="top">S peptide pool</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">Individual S peptide</td><td align="left" valign="top">Genscript</td><td align="left" valign="top"/><td align="left" valign="top">a peptide scan (15mers with 11 aa overlap) through S protein (Swiss-Prot ID: P0DTC2)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pMX-IRES-rat CD2 (plasmid)</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib45">Yamasaki et al., 2006</xref></td><td align="left" valign="top"/><td align="left" valign="top">retroviral vector</td></tr><tr><td align="left" valign="top">Cell line (Cercopithecus aethilops)</td><td align="left" valign="top">Vero E6/TMPRSS2</td><td align="left" valign="top">JCRB cell bank; <xref ref-type="bibr" rid="bib46">Yoshida et al., 2021</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="top">NFAT-GFP Reporter cell</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib31">Matsumoto et al., 2021</xref></td><td align="left" valign="top"/><td align="left" valign="top">T cell hybridoma lacking endogenous TCR with an NFAT-GFP reporter gene</td></tr><tr><td align="left" valign="top">Biological sample (Human gammaherpesvirus 4)</td><td align="left" valign="top">Epstein-Barr virus (EBV)</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib20">Kanda et al., 2015</xref></td><td align="left" valign="top"/><td align="left" valign="top">For B cell transformation</td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">GraphPad Prism 8</td><td align="left" valign="top">GraphPad Software</td><td align="left" valign="top">GraphPad Prism 8</td><td align="left" valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Sample collection</title><p>Samples (serum, whole blood, and PBMCs) were collected four times at 0–7 days before 1st dose vaccination as pre-vaccination, at 14–21 days after 1st dose vaccination as 3 weeks sample, at 35–49 days after 1st dose vaccination as 6 weeks sample, and at 154–182 days after 1st dose of vaccination as 24 weeks sample. At the same time of blood sampling, adverse event information was also collected from all participants. PBMCs were isolated using BD vacutainer CPT cell separation tube (Beckton Dickinson), according to manufacturers’ instructions. Isolated PBMCs were stored in the vapor phase of liquid nitrogen until use.</p></sec><sec id="s4-2"><title>Antibody titer determination by enzyme-linked immunosorbent assay (ELISA)</title><p>Serum antibody titer was measured using ELISA. Briefly, recombinant ancestral S protein (S1 + S2, Cell Signaling Technology; 1 µg/ml) or recombinant nucleocapsid protein (Acrobiosystems; 1 µg/ml) was coated on 96-well plate at 4 °C overnight. On the second day, wells were blocked with goat serum (Gibco) for 2 hr at room temperature. The sera were diluted from 10 to 31,250 folds in blocking buffer and incubated overnight at 4 °C. The next day, wells were washed and incubated with horseradish peroxidase (HRP)-conjugated antibodies (Abcam) for 3 hr at room temperature. After being washed with PBS-T (0.05% tween 20), wells were incubated with the peroxidase chromogenic substrate 3,3’–5,5’-tetramethyl benzidine (Sigma-Aldrich) for 30 min at room temperature, then the reaction was stopped by 0.5 N sulfuric acid (Sigma Aldrich). The absorbance of wells was immediately measured at 450 nm with a microplate reader (Bio-Rad). The value of the half-maximal antibody titer of each sample was calculated from the highest absorbance in the dilution range by using Prism 8 software. The calculated antibody titer was converted to BAU/ml by using WHO International Standard 20/136 (NIBSC) for ancestral S-specific antibody titer.</p></sec><sec id="s4-3"><title>Whole blood interferon-gamma release immune assay (IGRA) for SARS-CoV-2-specific T cell responses using QuantiFERON</title><p>SARS-CoV-2 specific T cell immune responses were evaluated by QuantiFERON SARS-CoV-2 (Qiagen) (<xref ref-type="bibr" rid="bib16">Jaganathan et al., 2021</xref>), according to manufacturer’s instructions, in which CD4<sup>+</sup> T cells were activated by epitopes coated on Ag1 tube, and CD4<sup>+</sup> and CD8<sup>+</sup> T cells were activated by epitopes coated on Ag2 tube. Briefly, 1 ml of whole blood sample with heparin is added into each of Nil (negative control), Mito (positive control), Ag1, and Ag2 tubes, and incubated at 37 °C for 22–24 hr. Tubes were then centrifuged at 3000×<italic>g</italic> for 15 min for collecting plasma samples. IFNγ derived from activated T cells was measured with enzyme-linked immunosorbent assay (ELISA) (Qiangen) according to the manufacturer’s instructions. IFNγ concentration (IU/ml) was calculated with background (Nil tube) subtracted from values of Ag1 or Ag2 tubes.</p></sec><sec id="s4-4"><title>Pseudo-typed virus neutralization assay</title><p>The neutralizing activity of serum antibodies was analyzed with pseudo-typed VSVs as previously described (<xref ref-type="bibr" rid="bib46">Yoshida et al., 2021</xref>). Briefly, Vero E6 cells stably expressing TMPRSS2 were seeded on 96-well plates and incubated at 37 °C for 24 h. Pseudoviruses were incubated with a series of dilutions of inactivated serum for 1 hr at 37 °C, then added to Vero E6 cells. At 24 hr after infection, cells were lysed with cell culture lysis reagent (Promega), and luciferase activity was measured by Centro XS<sup>3</sup> LB 960 (Berthold).</p></sec><sec id="s4-5"><title>In vitro stimulation of PBMCs</title><p>Cryopreserved PBMCs were thawed and washed with warm RPMI 1640 medium (Sigma) supplemented with 5% human AB serum (GeminiBio), Penicillin (Sigma), streptomycin (MP Biomedicals), and 2-mercaptoethanol (Nacalai Tesque). PBMCs were labeled with Cell Proliferation Kit (CellTrace Violet, ThermoFisher) following the manufacturer’s protocol and were stimulated in the same medium with S peptide pool (1 μg/ml per peptide, JPT) for 10 days, with human recombinant IL-2 (1 ng/ml, Peprotech), IL-7 (5 ng/ml, BioLegend) and IL-15 (5 ng/ml, Peprotech) supplemented on day 2, day 5, and day 8 of the culture. On day 10 cells were washed and stained with anti-human CD3 and TotalSeq-C Hashtags antibodies. Proliferated T cells (CD3<sup>+</sup>CTV<sup>low</sup>) were sorted by cell sorter SH800S (SONY) and used for single-cell TCR and RNA sequencing analyses.</p></sec><sec id="s4-6"><title>Single-cell-based transcriptome and TCR repertoire analysis</title><p>Single cell library was prepared using the reagents from 10x Genomics following the manufacturer’s instructions. After reverse transcription, cDNA was amplified for 14 cycles, and up to 50 ng of cDNA was used for construction of gene expression and TCR libraries. Libraries were sequenced in paired-end mode, and the raw reads were processed by Cell Ranger 6.0.0 (10x Genomics). Distribution of the mitochondrial gene percentage, n_counts and n_genes were fitted with a one-variable, two-component mixed Gaussian model using the Python package scikit-learn (<xref ref-type="bibr" rid="bib36">Pedregosa et al., 2011</xref>) and divided into two distributions corresponding to high and low levels, respectively. The cutting threshold values were the middle value of the means of the two fitted Gaussian distributions. A package call Scrublet was also applied (<xref ref-type="bibr" rid="bib44">Wolock et al., 2019</xref>), and the events whose main hashtag reads are less than 95% of the total hashtag reads were gated out before the UMAP plots were exported using BBrowser (<xref ref-type="bibr" rid="bib24">Le et al., 2020</xref>). Tfh signature score was generated using canonical Tfh marker genes (<italic>IL21</italic>, <italic>ICOS</italic>, <italic>CD200, PDCD1</italic>, <italic>POU2AF1</italic>, <italic>BTLA</italic>, <italic>CXCR5,</italic> and <italic>CXCL13</italic>). Other cell populations were annotated using the following markers: Treg, <italic>CD4</italic><sup>+</sup><italic>FOXP3</italic><sup>+</sup>; CD4T, <italic>CD3E</italic><sup>+</sup><italic>CD4</italic><sup>+</sup>; CD8T, <italic>CD3E</italic><sup>+</sup><italic>CD8A</italic><sup>+</sup>; central memory (cm) cells, <italic>SELL</italic>(CD62L)<sup>hi</sup> cells although sometimes <italic>CCR7</italic> expression is vague; effector memory (em) cells, <italic>SELL</italic><sup>low/–</sup><italic>CCR7</italic><sup>–</sup> and <italic>IFNG</italic>-expressing cells containing populations; naïve cells, <italic>CCR7</italic><sup>+</sup><italic>TCF7</italic><sup>+</sup>; cycling cells, <italic>MKI67</italic><sup>hi</sup>; γδT, <italic>TRDC</italic><sup>+</sup>; B cells, <italic>CD19</italic><sup>+</sup>; Monocyte, <italic>CD14</italic><sup>+</sup>; MAIT, <italic>CD3E</italic><sup>+</sup><italic>KLRB1</italic><sup>+</sup><italic>IL18R1</italic><sup>+</sup>; Tfr, <italic>FOXP3</italic><sup>+</sup><italic>NRN1</italic><sup>+</sup> in cells with high Tfh score; CD4-CTL, <italic>GZMB</italic><sup>+</sup> in CD4T cells (<xref ref-type="bibr" rid="bib19">Kaech et al., 2002</xref>; <xref ref-type="bibr" rid="bib32">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Sallusto et al., 2004</xref>; <xref ref-type="bibr" rid="bib43">Wang et al., 2021</xref>).</p></sec><sec id="s4-7"><title>Reporter cell establishment and stimulation</title><p>TCRα and β chain cDNA sequences were introduced into a mouse T cell hybridoma lacking TCR and having a nuclear factor of activated T-cells (NFAT)-green fluorescent protein (GFP) reporter gene (<xref ref-type="bibr" rid="bib31">Matsumoto et al., 2021</xref>) using retroviral vectors (<xref ref-type="bibr" rid="bib29">Lu et al., 2021</xref>; <xref ref-type="bibr" rid="bib45">Yamasaki et al., 2006</xref>). TCR-reconstituted cells were co-cultured with 1 μg/ml of peptides in the presence of antigen-presenting cells (APCs). After 20 hr, cell activation was assessed by GFP and CD69 expression.</p></sec><sec id="s4-8"><title>Antigen-presenting cells</title><p>Transformed B cells and HLA-transfected HEK293T cells used as APCs were generated as described (<xref ref-type="bibr" rid="bib29">Lu et al., 2021</xref>). For transformed B cells, 3×10<sup>5</sup> PBMCs were incubated with the recombinant Epstein-Barr virus (EBV) suspension (<xref ref-type="bibr" rid="bib20">Kanda et al., 2015</xref>) for 1 hr at 37 °C with mild shaking every 15 min. The infected cells were cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum (FBS, CAPRICORN SCIENTIFIC GmbH) containing cyclosporine A (CsA, 0.1 μg/ml, Cayman Chemical). Immortalized B lymphoblastoid cell lines were obtained after 3 weeks of culture and used as APCs. For HLA-transfected HEK293T cells, plasmids encoding HLA class I/II alleles (<xref ref-type="bibr" rid="bib17">Jiang et al., 2013</xref>) were transfected in HEK293T cells with PEI MAX (Polysciences).</p></sec><sec id="s4-9"><title>Determination of epitopes and restricting HLA</title><p>15-mer peptides with 11 amino acids overlap that cover the full length of S protein of SARS-CoV-2 were synthesized (GenScript). Peptides were dissolved in DMSO at 12 mg/ml and 12–15 peptides were mixed to create 26 different semi-pools. TCR-reconstituted reporter cells were stimulated with 1 μg/ml of S peptide pool (1 μg/ml per peptide, JPT), then 36-peptide pools that consist of three semi-pools each, then semi-pools, and then 12 individual peptides in the presence of autologous B cells to identify epitope peptides. To determine the restricting HLA, HLAs were narrowed down by co-culturing reporter cells with autologous and various heterologous B cells in the presence of 1 μg/ml of the epitope peptide. HLAs shared by activatable B cells were transduced in HEK239T cells and used for further co-culture to identify the restricting HLA.</p></sec><sec id="s4-10"><title>Statistics</title><p>All values with error bars are presented as the mean ± SEM. One-way ANOVA followed by Turkey’s post hoc multiple comparison test was used to assess significant differences in each experiment using Prism 8 software (GraphPad Software). Differences were considered to be significant when p value was less than 0.05. p values in <xref ref-type="fig" rid="fig6">Figure 6</xref> were calculated with t-test using the ‘stat_compare_means’ function in R (version 4.3.0 for arm64).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Works in the Department of Health Development and Medicine, which is an endowed department supported by AnGes, Daicel, and FunPep</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This project was approved by Osaka University Institutional Review Board (IRB) (reference No. 21487). 43 volunteers were enrolled in this project. Informed consent was obtained from all participants before the first blood sampling.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-89999-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Scripts for analysis of single-cell sequencing data.</title></caption><media xlink:href="elife-89999-code1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Single cell-based transcriptome data have been deposited in Gene Expression Omnibus (GEO) datasets (accession number GSE246535). Other data needed to support the conclusion of this manuscript are included in the main text and supplemental information.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Motooka</surname><given-names>D</given-names></name><name><surname>Nakagami</surname><given-names>H</given-names></name><name><surname>Yamasaki</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>T cell responses in SARS-CoV-2 vaccinees with sustained or declined antibody titer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246535">GSE246535</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank S Iwai, Y Sakai, C Günther, J Sun, and Y Yanagida for experimental support, D Motooka, D Okuzaki, and YC Liu for bioinformatic data analysis and C Schutt and Y Yamagishi for discussion. This research was supported by Japan Agency for Medical Research and Development (JP223fa627002, JP223fa727001, JP23ym0126049 (SY), JP21ym0126049 (HN)) and Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (JP20H00505, JP22H05182, JP22H05183 (SY)). The Department of Health Development and Medicine is an endowed department supported by AnGes, Daicel, and FunPep.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>N</given-names></name><name><surname>Stowe</surname><given-names>J</given-names></name><name><surname>Kirsebom</surname><given-names>F</given-names></name><name><surname>Toffa</surname><given-names>S</given-names></name><name><surname>Rickeard</surname><given-names>T</given-names></name><name><surname>Gallagher</surname><given-names>E</given-names></name><name><surname>Gower</surname><given-names>C</given-names></name><name><surname>Kall</surname><given-names>M</given-names></name><name><surname>Groves</surname><given-names>N</given-names></name><name><surname>O’Connell</surname><given-names>A-M</given-names></name><name><surname>Simons</surname><given-names>D</given-names></name><name><surname>Blomquist</surname><given-names>PB</given-names></name><name><surname>Zaidi</surname><given-names>A</given-names></name><name><surname>Nash</surname><given-names>S</given-names></name><name><surname>Iwani Binti Abdul Aziz</surname><given-names>N</given-names></name><name><surname>Thelwall</surname><given-names>S</given-names></name><name><surname>Dabrera</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Amirthalingam</surname><given-names>G</given-names></name><name><surname>Gharbia</surname><given-names>S</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Elson</surname><given-names>R</given-names></name><name><surname>Ladhani</surname><given-names>SN</given-names></name><name><surname>Ferguson</surname><given-names>N</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>CNJ</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Hopkins</surname><given-names>S</given-names></name><name><surname>Chand</surname><given-names>M</given-names></name><name><surname>Ramsay</surname><given-names>M</given-names></name><name><surname>Lopez Bernal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant</article-title><source>The New England Journal of Medicine</source><volume>386</volume><fpage>1532</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2119451</pub-id><pub-id pub-id-type="pmid">35249272</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>H</given-names></name><name><surname>Kitabatake</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name><name><surname>Shichino</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>A</given-names></name><name><surname>Ouji-Sageshima</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Ueha</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>T cell responses induced by sars-cov-2 mrna vaccination are associated with clonal replacement</article-title><source>SSRN Electronic Journal</source><volume>01</volume><elocation-id>2457</elocation-id><pub-id pub-id-type="doi">10.2139/ssrn.4232457</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Esser</surname><given-names>D</given-names></name><name><surname>Martini</surname><given-names>GR</given-names></name><name><surname>Saggau</surname><given-names>C</given-names></name><name><surname>Schiminsky</surname><given-names>E</given-names></name><name><surname>Dargvainiene</surname><given-names>J</given-names></name><name><surname>Schröder</surname><given-names>I</given-names></name><name><surname>Wieters</surname><given-names>I</given-names></name><name><surname>Khodamoradi</surname><given-names>Y</given-names></name><name><surname>Eberhardt</surname><given-names>F</given-names></name><name><surname>Vehreschild</surname><given-names>M</given-names></name><name><surname>Neb</surname><given-names>H</given-names></name><name><surname>Sonntagbauer</surname><given-names>M</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>F</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Markewitz</surname><given-names>R</given-names></name><name><surname>Wandinger</surname><given-names>KP</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name><name><surname>Kochanek</surname><given-names>M</given-names></name><name><surname>Leypoldt</surname><given-names>F</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Koehler</surname><given-names>P</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Scheffold</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Low-Avidity CD4<sup>+</sup> T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19</article-title><source>Immunity</source><volume>53</volume><fpage>1258</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.016</pub-id><pub-id pub-id-type="pmid">33296686</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>LR</given-names></name><name><surname>El Sahly</surname><given-names>HM</given-names></name><name><surname>Essink</surname><given-names>B</given-names></name><name><surname>Kotloff</surname><given-names>K</given-names></name><name><surname>Frey</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>R</given-names></name><name><surname>Diemert</surname><given-names>D</given-names></name><name><surname>Spector</surname><given-names>SA</given-names></name><name><surname>Rouphael</surname><given-names>N</given-names></name><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>McGettigan</surname><given-names>J</given-names></name><name><surname>Khetan</surname><given-names>S</given-names></name><name><surname>Segall</surname><given-names>N</given-names></name><name><surname>Solis</surname><given-names>J</given-names></name><name><surname>Brosz</surname><given-names>A</given-names></name><name><surname>Fierro</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>H</given-names></name><name><surname>Neuzil</surname><given-names>K</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Gilbert</surname><given-names>P</given-names></name><name><surname>Janes</surname><given-names>H</given-names></name><name><surname>Follmann</surname><given-names>D</given-names></name><name><surname>Marovich</surname><given-names>M</given-names></name><name><surname>Mascola</surname><given-names>J</given-names></name><name><surname>Polakowski</surname><given-names>L</given-names></name><name><surname>Ledgerwood</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Pajon</surname><given-names>R</given-names></name><name><surname>Knightly</surname><given-names>C</given-names></name><name><surname>Leav</surname><given-names>B</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Ivarsson</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Zaks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title><source>New England Journal of Medicine</source><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolo</surname><given-names>L</given-names></name><name><surname>Afroz</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>YG</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>CF</given-names></name><name><surname>Tanes</surname><given-names>C</given-names></name><name><surname>Bittinger</surname><given-names>K</given-names></name><name><surname>Friedman</surname><given-names>ES</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Wu</surname><given-names>GD</given-names></name><name><surname>Su</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2-specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabn3127</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abn3127</pub-id><pub-id pub-id-type="pmid">35857619</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becerra-Artiles</surname><given-names>A</given-names></name><name><surname>Calvo-Calle</surname><given-names>JM</given-names></name><name><surname>Co</surname><given-names>MD</given-names></name><name><surname>Nanaware</surname><given-names>PP</given-names></name><name><surname>Cruz</surname><given-names>J</given-names></name><name><surname>Weaver</surname><given-names>GC</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Forconi</surname><given-names>C</given-names></name><name><surname>Finberg</surname><given-names>RW</given-names></name><name><surname>Moormann</surname><given-names>AM</given-names></name><name><surname>Stern</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles</article-title><source>Cell Reports</source><volume>39</volume><elocation-id>110952</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110952</pub-id><pub-id pub-id-type="pmid">35675811</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenna</surname><given-names>E</given-names></name><name><surname>Davydov</surname><given-names>AN</given-names></name><name><surname>Ladell</surname><given-names>K</given-names></name><name><surname>McLaren</surname><given-names>JE</given-names></name><name><surname>Bonaiuti</surname><given-names>P</given-names></name><name><surname>Metsger</surname><given-names>M</given-names></name><name><surname>Ramsden</surname><given-names>JD</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Campion</surname><given-names>SL</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CD4+ T follicular helper cells in human tonsils and blood are clonally convergent but divergent from non-Tfh CD4+ cells</article-title><source>Cell Reports</source><volume>30</volume><fpage>137</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.12.016</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collier</surname><given-names>DA</given-names></name><name><surname>De Marco</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>IATM</given-names></name><name><surname>Meng</surname><given-names>B</given-names></name><name><surname>Datir</surname><given-names>RP</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Kemp</surname><given-names>SA</given-names></name><name><surname>Bassi</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Silacci-Fregni</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Bowen</surname><given-names>J</given-names></name><name><surname>Culap</surname><given-names>K</given-names></name><name><surname>Jaconi</surname><given-names>S</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Pizzuto</surname><given-names>MS</given-names></name><name><surname>Pellanda</surname><given-names>AF</given-names></name><name><surname>Garzoni</surname><given-names>C</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><collab>CITIID-NIHR BioResource COVID-19 Collaboration</collab><name><surname>Elmer</surname><given-names>A</given-names></name><name><surname>Kingston</surname><given-names>N</given-names></name><name><surname>Graves</surname><given-names>B</given-names></name><name><surname>McCoy</surname><given-names>LE</given-names></name><name><surname>Smith</surname><given-names>KGC</given-names></name><name><surname>Bradley</surname><given-names>JR</given-names></name><name><surname>Temperton</surname><given-names>N</given-names></name><name><surname>Ceron-Gutierrez</surname><given-names>L</given-names></name><name><surname>Barcenas-Morales</surname><given-names>G</given-names></name><collab>COVID-19 Genomics UK (COG-UK) Consortium</collab><name><surname>Harvey</surname><given-names>W</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Piccoli</surname><given-names>L</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Wills</surname><given-names>M</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies</article-title><source>Nature</source><volume>593</volume><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03412-7</pub-id><pub-id pub-id-type="pmid">33706364</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>Walker</surname><given-names>SC</given-names></name><name><surname>Samuels</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 Vaccines</article-title><source>JAMA</source><volume>325</volume><fpage>1318</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.3199</pub-id><pub-id pub-id-type="pmid">33635317</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>T follicular helper cell biology: A decade of discovery and diseases</article-title><source>Immunity</source><volume>50</volume><fpage>1132</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.04.011</pub-id><pub-id pub-id-type="pmid">31117010</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>RO</given-names></name><name><surname>DeWitt</surname><given-names>WS</given-names></name><name><surname>Vignali</surname><given-names>M</given-names></name><name><surname>Gravley</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>JK</given-names></name><name><surname>Osborne</surname><given-names>EJ</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name><name><surname>Rieder</surname><given-names>M</given-names></name><name><surname>Robins</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire</article-title><source>Nature Genetics</source><volume>49</volume><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/ng.3822</pub-id><pub-id pub-id-type="pmid">28369038</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GeurtsvanKessel</surname><given-names>CH</given-names></name><name><surname>Geers</surname><given-names>D</given-names></name><name><surname>Schmitz</surname><given-names>KS</given-names></name><name><surname>Mykytyn</surname><given-names>AZ</given-names></name><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Bogers</surname><given-names>S</given-names></name><name><surname>Scherbeijn</surname><given-names>S</given-names></name><name><surname>Gommers</surname><given-names>L</given-names></name><name><surname>Sablerolles</surname><given-names>RSG</given-names></name><name><surname>Nieuwkoop</surname><given-names>NN</given-names></name><name><surname>Rijsbergen</surname><given-names>LC</given-names></name><name><surname>van Dijk</surname><given-names>LLA</given-names></name><name><surname>de Wilde</surname><given-names>J</given-names></name><name><surname>Alblas</surname><given-names>K</given-names></name><name><surname>Breugem</surname><given-names>TI</given-names></name><name><surname>Rijnders</surname><given-names>BJA</given-names></name><name><surname>de Jager</surname><given-names>H</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>van der Kuy</surname><given-names>PHM</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Koopmans</surname><given-names>MPG</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>de Vries</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabo2202</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abo2202</pub-id><pub-id pub-id-type="pmid">35113647</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Pei</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>6588</fpage><lpage>6599</lpage><pub-id pub-id-type="doi">10.1172/JCI141054</pub-id><pub-id pub-id-type="pmid">32841212</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Premkumar</surname><given-names>L</given-names></name><name><surname>Jadi</surname><given-names>RS</given-names></name><name><surname>Marrama</surname><given-names>D</given-names></name><name><surname>de Silva</surname><given-names>AM</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Carlin</surname><given-names>AF</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targets of t cell responses to sars-cov-2 coronavirus in humans with covid-19 disease and unexposed individuals</article-title><source>Cell</source><volume>181</volume><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characteristics of sars-cov-2 and covid-19</article-title><source>Nature Reviews. Microbiology</source><volume>19</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00459-7</pub-id><pub-id pub-id-type="pmid">33024307</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaganathan</surname><given-names>S</given-names></name><name><surname>Stieber</surname><given-names>F</given-names></name><name><surname>Rao</surname><given-names>SN</given-names></name><name><surname>Nikolayevskyy</surname><given-names>V</given-names></name><name><surname>Manissero</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>N</given-names></name><name><surname>Boyle</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Preliminary evaluation of quantiferon sars-cov-2 and qiareach anti-sars-cov-2 total test in recently vaccinated individuals</article-title><source>Infectious Diseases and Therapy</source><volume>10</volume><fpage>2765</fpage><lpage>2776</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00521-8</pub-id><pub-id pub-id-type="pmid">34435336</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Arase</surname><given-names>N</given-names></name><name><surname>Kohyama</surname><given-names>M</given-names></name><name><surname>Hirayasu</surname><given-names>K</given-names></name><name><surname>Suenaga</surname><given-names>T</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Shida</surname><given-names>K</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Arase</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules</article-title><source>International Immunology</source><volume>25</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxs155</pub-id><pub-id pub-id-type="pmid">23334921</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juno</surname><given-names>JA</given-names></name><name><surname>Tan</surname><given-names>HX</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Reynaldi</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>HG</given-names></name><name><surname>Wragg</surname><given-names>K</given-names></name><name><surname>Esterbauer</surname><given-names>R</given-names></name><name><surname>Kent</surname><given-names>HE</given-names></name><name><surname>Batten</surname><given-names>CJ</given-names></name><name><surname>Mordant</surname><given-names>FL</given-names></name><name><surname>Gherardin</surname><given-names>NA</given-names></name><name><surname>Pymm</surname><given-names>P</given-names></name><name><surname>Dietrich</surname><given-names>MH</given-names></name><name><surname>Scott</surname><given-names>NE</given-names></name><name><surname>Tham</surname><given-names>WH</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Davenport</surname><given-names>MP</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1428</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0995-0</pub-id><pub-id pub-id-type="pmid">32661393</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaech</surname><given-names>SM</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Effector and memory T-cell differentiation: implications for vaccine development</article-title><source>Nature Reviews. Immunology</source><volume>2</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nri778</pub-id><pub-id pub-id-type="pmid">12001996</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Miyata</surname><given-names>M</given-names></name><name><surname>Kano</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Yoshizaki</surname><given-names>T</given-names></name><name><surname>Iizasa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clustered microRNAs of the Epstein-Barr virus cooperatively downregulate an epithelial cell-specific metastasis suppressor</article-title><source>Journal of Virology</source><volume>89</volume><fpage>2684</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1128/JVI.03189-14</pub-id><pub-id pub-id-type="pmid">25520514</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>N</given-names></name><name><surname>Kuo</surname><given-names>HH</given-names></name><name><surname>Boucau</surname><given-names>J</given-names></name><name><surname>Farmer</surname><given-names>JR</given-names></name><name><surname>Allard-Chamard</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Piechocka-Trocha</surname><given-names>A</given-names></name><name><surname>Lefteri</surname><given-names>K</given-names></name><name><surname>Osborn</surname><given-names>M</given-names></name><name><surname>Bals</surname><given-names>J</given-names></name><name><surname>Bartsch</surname><given-names>YC</given-names></name><name><surname>Bonheur</surname><given-names>N</given-names></name><name><surname>Caradonna</surname><given-names>TM</given-names></name><name><surname>Chevalier</surname><given-names>J</given-names></name><name><surname>Chowdhury</surname><given-names>F</given-names></name><name><surname>Diefenbach</surname><given-names>TJ</given-names></name><name><surname>Einkauf</surname><given-names>K</given-names></name><name><surname>Fallon</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Finn</surname><given-names>KK</given-names></name><name><surname>Garcia-Broncano</surname><given-names>P</given-names></name><name><surname>Hartana</surname><given-names>CA</given-names></name><name><surname>Hauser</surname><given-names>BM</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Kaplonek</surname><given-names>P</given-names></name><name><surname>Karpell</surname><given-names>M</given-names></name><name><surname>Koscher</surname><given-names>EC</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ly</surname><given-names>NL</given-names></name><name><surname>Michell</surname><given-names>AR</given-names></name><name><surname>Rassadkina</surname><given-names>Y</given-names></name><name><surname>Seiger</surname><given-names>K</given-names></name><name><surname>Sessa</surname><given-names>L</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ticheli</surname><given-names>HJ</given-names></name><name><surname>Waring</surname><given-names>MT</given-names></name><name><surname>Zhu</surname><given-names>AL</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Lichterfeld</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Padera</surname><given-names>RF</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of bcl-6-expressing t follicular helper cells and germinal centers in covid-19</article-title><source>Cell</source><volume>183</volume><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.025</pub-id><pub-id pub-id-type="pmid">32877699</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeton</surname><given-names>R</given-names></name><name><surname>Tincho</surname><given-names>MB</given-names></name><name><surname>Ngomti</surname><given-names>A</given-names></name><name><surname>Baguma</surname><given-names>R</given-names></name><name><surname>Benede</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Cele</surname><given-names>S</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Karim</surname><given-names>F</given-names></name><name><surname>Madzorera</surname><given-names>SV</given-names></name><name><surname>Moyo-Gwete</surname><given-names>T</given-names></name><name><surname>Mennen</surname><given-names>M</given-names></name><name><surname>Skelem</surname><given-names>S</given-names></name><name><surname>Adriaanse</surname><given-names>M</given-names></name><name><surname>Mutithu</surname><given-names>D</given-names></name><name><surname>Aremu</surname><given-names>O</given-names></name><name><surname>Stek</surname><given-names>C</given-names></name><name><surname>du Bruyn</surname><given-names>E</given-names></name><name><surname>Van Der Mescht</surname><given-names>MA</given-names></name><name><surname>de Beer</surname><given-names>Z</given-names></name><name><surname>de Villiers</surname><given-names>TR</given-names></name><name><surname>Bodenstein</surname><given-names>A</given-names></name><name><surname>van den Berg</surname><given-names>G</given-names></name><name><surname>Mendes</surname><given-names>A</given-names></name><name><surname>Strydom</surname><given-names>A</given-names></name><name><surname>Venter</surname><given-names>M</given-names></name><name><surname>Giandhari</surname><given-names>J</given-names></name><name><surname>Naidoo</surname><given-names>Y</given-names></name><name><surname>Pillay</surname><given-names>S</given-names></name><name><surname>Tegally</surname><given-names>H</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>de Oliveira</surname><given-names>T</given-names></name><name><surname>Bekker</surname><given-names>L-G</given-names></name><name><surname>Gray</surname><given-names>G</given-names></name><name><surname>Ueckermann</surname><given-names>V</given-names></name><name><surname>Rossouw</surname><given-names>T</given-names></name><name><surname>Boswell</surname><given-names>MT</given-names></name><name><surname>Bhiman</surname><given-names>JN</given-names></name><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name><name><surname>Ntusi</surname><given-names>NAB</given-names></name><name><surname>Burgers</surname><given-names>WA</given-names></name><name><surname>Riou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>T cell responses to SARS-CoV-2 spike cross-recognize Omicron</article-title><source>Nature</source><volume>603</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id><pub-id pub-id-type="pmid">35102311</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krammer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 vaccines in development</article-title><source>Nature</source><volume>586</volume><fpage>516</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2798-3</pub-id><pub-id pub-id-type="pmid">32967006</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Phan</surname><given-names>T</given-names></name><name><surname>Pham</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>D</given-names></name><name><surname>Lam</surname><given-names>L</given-names></name><name><surname>Tung</surname><given-names>N</given-names></name><name><surname>Truong</surname><given-names>T</given-names></name><name><surname>Vuong</surname><given-names>H</given-names></name><name><surname>Luu</surname><given-names>T</given-names></name><name><surname>Phung</surname><given-names>N</given-names></name><name><surname>Ngan</surname><given-names>P</given-names></name><name><surname>Trang</surname><given-names>N</given-names></name><name><surname>Pham</surname><given-names>O</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>HA</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>N</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Boysen</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>U</given-names></name><name><surname>Pham</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Ngoc</surname><given-names>P</given-names></name><name><surname>Gill</surname><given-names>T</given-names></name><name><surname>Pham</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BBrowser: Making Single-Cell Data Easily Accessible</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.11.414136</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Chng</surname><given-names>MHY</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>N</given-names></name><name><surname>Linster</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>WN</given-names></name><name><surname>Chen</surname><given-names>MI-C</given-names></name><name><surname>Wang</surname><given-names>L-F</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Kalimuddin</surname><given-names>S</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Low</surname><given-names>JG-H</given-names></name><name><surname>Tan</surname><given-names>Y-J</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title><source>Nature</source><volume>584</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id><pub-id pub-id-type="pmid">32668444</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>EG</given-names></name><name><surname>Lustig</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Fluss</surname><given-names>R</given-names></name><name><surname>Indenbaum</surname><given-names>V</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><name><surname>Doolman</surname><given-names>R</given-names></name><name><surname>Asraf</surname><given-names>K</given-names></name><name><surname>Mendelson</surname><given-names>E</given-names></name><name><surname>Ziv</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>C</given-names></name><name><surname>Freedman</surname><given-names>L</given-names></name><name><surname>Kreiss</surname><given-names>Y</given-names></name><name><surname>Regev-Yochay</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Waning immune humoral response to bnt162b2 covid-19 vaccine over 6 months</article-title><source>The New England Journal of Medicine</source><volume>385</volume><elocation-id>e84</elocation-id><pub-id pub-id-type="doi">10.1056/NEJMoa2114583</pub-id><pub-id pub-id-type="pmid">34614326</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>JS</given-names></name><name><surname>Vaqueirinho</surname><given-names>D</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Foglierini</surname><given-names>M</given-names></name><name><surname>Jerak</surname><given-names>J</given-names></name><name><surname>Perotti</surname><given-names>M</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Jovic</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>L</given-names></name><name><surname>Cacciatore</surname><given-names>R</given-names></name><name><surname>Terrot</surname><given-names>T</given-names></name><name><surname>Pellanda</surname><given-names>AF</given-names></name><name><surname>Biggiogero</surname><given-names>M</given-names></name><name><surname>Garzoni</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Ceschi</surname><given-names>A</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Cassotta</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2</article-title><source>Science</source><volume>372</volume><fpage>1336</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1126/science.abg8985</pub-id><pub-id pub-id-type="pmid">34006597</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyal</surname><given-names>L</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Henze</surname><given-names>L</given-names></name><name><surname>Kruse</surname><given-names>B</given-names></name><name><surname>Dingeldey</surname><given-names>M</given-names></name><name><surname>Reimer</surname><given-names>U</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Mangold</surname><given-names>M</given-names></name><name><surname>Unger</surname><given-names>C</given-names></name><name><surname>Dörfler</surname><given-names>F</given-names></name><name><surname>Kadler</surname><given-names>S</given-names></name><name><surname>Rosowski</surname><given-names>J</given-names></name><name><surname>Gürcan</surname><given-names>K</given-names></name><name><surname>Uyar-Aydin</surname><given-names>Z</given-names></name><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Schnatbaum</surname><given-names>K</given-names></name><name><surname>Eckey</surname><given-names>M</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Hocke</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Miltenyi</surname><given-names>S</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Mall</surname><given-names>MA</given-names></name><name><surname>Wenschuh</surname><given-names>H</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Lauster</surname><given-names>R</given-names></name><name><surname>Lachman</surname><given-names>N</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Röhmel</surname><given-names>J</given-names></name><name><surname>Meyer-Arndt</surname><given-names>L</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Giesecke-Thiel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross-reactive CD4<sup>+</sup> T cells enhance SARS-CoV-2 immune responses upon infection and vaccination</article-title><source>Science</source><volume>374</volume><elocation-id>eabh1823</elocation-id><pub-id pub-id-type="doi">10.1126/science.abh1823</pub-id><pub-id pub-id-type="pmid">34465633</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Hosono</surname><given-names>Y</given-names></name><name><surname>Nagae</surname><given-names>M</given-names></name><name><surname>Ishizuka</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>E</given-names></name><name><surname>Motooka</surname><given-names>D</given-names></name><name><surname>Ozaki</surname><given-names>Y</given-names></name><name><surname>Sax</surname><given-names>N</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Shinnakasu</surname><given-names>R</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Shinkai</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>EE</given-names></name><name><surname>Shioda</surname><given-names>T</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kumanogoh</surname><given-names>A</given-names></name><name><surname>Arase</surname><given-names>H</given-names></name><name><surname>Nakagami</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Yamasaki</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20211327</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20211327</pub-id><pub-id pub-id-type="pmid">34647971</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Burger</surname><given-names>ZC</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Lammers</surname><given-names>M</given-names></name><name><surname>Rubiro</surname><given-names>P</given-names></name><name><surname>Quiambao</surname><given-names>L</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>da Silva Antunes</surname><given-names>R</given-names></name><name><surname>Greenbaum</surname><given-names>J</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Markmann</surname><given-names>AJ</given-names></name><name><surname>Premkumar</surname><given-names>L</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title><source>Science</source><volume>370</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><pub-id pub-id-type="pmid">32753554</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Kishida</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>S</given-names></name><name><surname>Kohyama</surname><given-names>M</given-names></name><name><surname>Suenaga</surname><given-names>T</given-names></name><name><surname>Arase</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A TCR-like antibody against A proinsulin-containing fusion peptide ameliorates type 1 diabetes in NOD mice</article-title><source>Biochemical and Biophysical Research Communications</source><volume>534</volume><fpage>680</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.11.019</pub-id><pub-id pub-id-type="pmid">33208230</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meckiff</surname><given-names>BJ</given-names></name><name><surname>Ramírez-Suástegui</surname><given-names>C</given-names></name><name><surname>Fajardo</surname><given-names>V</given-names></name><name><surname>Chee</surname><given-names>SJ</given-names></name><name><surname>Kusnadi</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name><name><surname>Eschweiler</surname><given-names>S</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Pelosi</surname><given-names>E</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Ay</surname><given-names>F</given-names></name><name><surname>Seumois</surname><given-names>G</given-names></name><name><surname>Ottensmeier</surname><given-names>CH</given-names></name><name><surname>Vijayanand</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4<sup>+</sup> T Cells in COVID-19</article-title><source>Cell</source><volume>183</volume><fpage>1340</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.001</pub-id><pub-id pub-id-type="pmid">33096020</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudd</surname><given-names>PA</given-names></name><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Turner</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Kalaidina</surname><given-names>E</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Schmitz</surname><given-names>AJ</given-names></name><name><surname>Lei</surname><given-names>T</given-names></name><name><surname>Haile</surname><given-names>A</given-names></name><name><surname>Kirk</surname><given-names>AM</given-names></name><name><surname>Mettelman</surname><given-names>RC</given-names></name><name><surname>Crawford</surname><given-names>JC</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Rowntree</surname><given-names>LC</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Richards</surname><given-names>KA</given-names></name><name><surname>Sant</surname><given-names>AJ</given-names></name><name><surname>Klebert</surname><given-names>MK</given-names></name><name><surname>Suessen</surname><given-names>T</given-names></name><name><surname>Middleton</surname><given-names>WD</given-names></name><collab>SJTRC Study Team</collab><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Teefey</surname><given-names>SA</given-names></name><name><surname>O’Halloran</surname><given-names>JA</given-names></name><name><surname>Presti</surname><given-names>RM</given-names></name><name><surname>Kedzierska</surname><given-names>K</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Ellebedy</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans</article-title><source>Cell</source><volume>185</volume><fpage>603</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.12.026</pub-id><pub-id pub-id-type="pmid">35026152</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>RW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Venezia</surname><given-names>OL</given-names></name><name><surname>Majerus</surname><given-names>RM</given-names></name><name><surname>Shin</surname><given-names>DS</given-names></name><collab>MGH COVID-19 Collection &amp; Processing Team</collab><name><surname>Carrington</surname><given-names>MN</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Wesemann</surname><given-names>DR</given-names></name><name><surname>Moon</surname><given-names>JJ</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 epitope-specific CD4<sup>+</sup> memory T cell responses across COVID-19 disease severity and antibody durability</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabl9464</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abl9464</pub-id><pub-id pub-id-type="pmid">35857584</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>S</given-names></name><name><surname>Vignali</surname><given-names>M</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Dines</surname><given-names>JN</given-names></name><name><surname>Kaplan</surname><given-names>IM</given-names></name><name><surname>Svejnoha</surname><given-names>E</given-names></name><name><surname>Craft</surname><given-names>T</given-names></name><name><surname>Boland</surname><given-names>K</given-names></name><name><surname>Pesesky</surname><given-names>M</given-names></name><name><surname>Gittelman</surname><given-names>RM</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Gooley</surname><given-names>CJ</given-names></name><name><surname>Semprini</surname><given-names>S</given-names></name><name><surname>Cerchione</surname><given-names>C</given-names></name><name><surname>Mazza</surname><given-names>M</given-names></name><name><surname>Delmonte</surname><given-names>OM</given-names></name><name><surname>Dobbs</surname><given-names>K</given-names></name><name><surname>Carreño-Tarragona</surname><given-names>G</given-names></name><name><surname>Barrio</surname><given-names>S</given-names></name><name><surname>Sambri</surname><given-names>V</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Goldman</surname><given-names>JD</given-names></name><name><surname>Heath</surname><given-names>JR</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Carlson</surname><given-names>JM</given-names></name><name><surname>Martinez-Lopez</surname><given-names>J</given-names></name><name><surname>Robins</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Large-Scale Database of T-Cell Receptor Beta (TCRβ) Sequences and Binding Associations from Natural and Synthetic Exposure to SARS-CoV-2</article-title><source>Research Square</source><pub-id pub-id-type="doi">10.21203/rs.3.rs-51964/v1</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedregosa</surname><given-names>F</given-names></name><name><surname>Varoquaux</surname><given-names>G</given-names></name><name><surname>Gramfort</surname><given-names>A</given-names></name><name><surname>Michel</surname><given-names>V</given-names></name><name><surname>Thirion</surname><given-names>B</given-names></name><name><surname>Grisel</surname><given-names>O</given-names></name><name><surname>Blondel</surname><given-names>M</given-names></name><name><surname>Prettenhofer</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Dubourg</surname><given-names>V</given-names></name><name><surname>Vanderplas</surname><given-names>J</given-names></name><name><surname>Passos</surname><given-names>A</given-names></name><name><surname>Cournapeau</surname><given-names>D</given-names></name><name><surname>Brucher</surname><given-names>M</given-names></name><name><surname>Perrot</surname><given-names>M</given-names></name><name><surname>Duchesnay</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Scikit-learn: machine learning in python</article-title><source>Journal of Machine Learning Research</source><volume>12</volume><fpage>2825</fpage><lpage>2830</lpage></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>O’Connell</surname><given-names>SE</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Talana</surname><given-names>CA</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Flach</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>L</given-names></name><name><surname>Leav</surname><given-names>B</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Luke</surname><given-names>CJ</given-names></name><name><surname>Makowski</surname><given-names>M</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name><name><surname>Roberts</surname><given-names>PC</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Rebolledo</surname><given-names>PA</given-names></name><name><surname>Rostad</surname><given-names>CA</given-names></name><name><surname>Rouphael</surname><given-names>NG</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Widge</surname><given-names>AT</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Arega</surname><given-names>J</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Buchanan</surname><given-names>W</given-names></name><name><surname>Elsafy</surname><given-names>M</given-names></name><name><surname>Hoang</surname><given-names>B</given-names></name><name><surname>Lampley</surname><given-names>R</given-names></name><name><surname>Kolhekar</surname><given-names>A</given-names></name><name><surname>Koo</surname><given-names>H</given-names></name><name><surname>Luke</surname><given-names>C</given-names></name><name><surname>Makhene</surname><given-names>M</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Pikaart-Tautges</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>PC</given-names></name><name><surname>Russell</surname><given-names>J</given-names></name><name><surname>Sindall</surname><given-names>E</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Kunwar</surname><given-names>P</given-names></name><name><surname>Makowski</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>EJ</given-names></name><name><surname>Bechnak</surname><given-names>A</given-names></name><name><surname>Bower</surname><given-names>M</given-names></name><name><surname>Camacho-Gonzalez</surname><given-names>AF</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Drobeniuc</surname><given-names>A</given-names></name><name><surname>Edara</surname><given-names>VV</given-names></name><name><surname>Edupuganti</surname><given-names>S</given-names></name><name><surname>Floyd</surname><given-names>K</given-names></name><name><surname>Gibson</surname><given-names>T</given-names></name><name><surname>Ackerley</surname><given-names>CMG</given-names></name><name><surname>Johnson</surname><given-names>B</given-names></name><name><surname>Kamidani</surname><given-names>S</given-names></name><name><surname>Kao</surname><given-names>C</given-names></name><name><surname>Kelley</surname><given-names>C</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Macenczak</surname><given-names>H</given-names></name><name><surname>McCullough</surname><given-names>MP</given-names></name><name><surname>Peters</surname><given-names>E</given-names></name><name><surname>Phadke</surname><given-names>VK</given-names></name><name><surname>Rebolledo</surname><given-names>PA</given-names></name><name><surname>Rostad</surname><given-names>CA</given-names></name><name><surname>Rouphael</surname><given-names>N</given-names></name><name><surname>Scherer</surname><given-names>E</given-names></name><name><surname>Sherman</surname><given-names>A</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>Teherani</surname><given-names>M</given-names></name><name><surname>Traenkner</surname><given-names>J</given-names></name><name><surname>Winston</surname><given-names>J</given-names></name><name><surname>Yildirim</surname><given-names>I</given-names></name><name><surname>Barr</surname><given-names>L</given-names></name><name><surname>Benoit</surname><given-names>J</given-names></name><name><surname>Carste</surname><given-names>B</given-names></name><name><surname>Choe</surname><given-names>J</given-names></name><name><surname>Dunstan</surname><given-names>M</given-names></name><name><surname>Erolin</surname><given-names>R</given-names></name><name><surname>Ffitch</surname><given-names>J</given-names></name><name><surname>Fields</surname><given-names>C</given-names></name><name><surname>Jackson</surname><given-names>LA</given-names></name><name><surname>Kiniry</surname><given-names>E</given-names></name><name><surname>Lasicka</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Pimienta</surname><given-names>S</given-names></name><name><surname>Suyehira</surname><given-names>J</given-names></name><name><surname>Witte</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Altaras</surname><given-names>NE</given-names></name><name><surname>Carfi</surname><given-names>A</given-names></name><name><surname>Hurley</surname><given-names>M</given-names></name><name><surname>Leav</surname><given-names>B</given-names></name><name><surname>Pajon</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zaks</surname><given-names>T</given-names></name><name><surname>Coler</surname><given-names>RN</given-names></name><name><surname>Larsen</surname><given-names>SE</given-names></name><name><surname>Neuzil</surname><given-names>KM</given-names></name><name><surname>Lindesmith</surname><given-names>LC</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Munt</surname><given-names>J</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Berkowitz</surname><given-names>NM</given-names></name><name><surname>Boritz</surname><given-names>EA</given-names></name><name><surname>Carlton</surname><given-names>K</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Costner</surname><given-names>P</given-names></name><name><surname>Creanga</surname><given-names>A</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Flach</surname><given-names>B</given-names></name><name><surname>Gaudinski</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>I</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Holman</surname><given-names>L</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>BC</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Morabito</surname><given-names>KM</given-names></name><name><surname>Novik</surname><given-names>L</given-names></name><name><surname>O’Connell</surname><given-names>S</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Padilla</surname><given-names>M</given-names></name><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Swanson</surname><given-names>PA</given-names></name><name><surname>Talana</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Widge</surname><given-names>AT</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Pruijssers</surname><given-names>AJ</given-names></name><name><surname>Stevens</surname><given-names>LJ</given-names></name><name><surname>Posavad</surname><given-names>CM</given-names></name><name><surname>Gale</surname><given-names>M</given-names></name><name><surname>Menachery</surname><given-names>V</given-names></name><name><surname>Shi</surname><given-names>P-Y</given-names></name><collab>mRNA-1273 Study Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants</article-title><source>Science</source><volume>373</volume><fpage>1372</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1126/science.abj4176</pub-id><pub-id pub-id-type="pmid">34385356</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>JL</given-names></name><name><surname>Pérez Marc</surname><given-names>G</given-names></name><name><surname>Moreira</surname><given-names>ED</given-names></name><name><surname>Zerbini</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Swanson</surname><given-names>KA</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Koury</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Kalina</surname><given-names>WV</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name><surname>Hammitt</surname><given-names>LL</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Nell</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Ünal</surname><given-names>S</given-names></name><name><surname>Tresnan</surname><given-names>DB</given-names></name><name><surname>Mather</surname><given-names>S</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Şahin</surname><given-names>U</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Gruber</surname><given-names>WC</given-names></name><collab>C4591001 Clinical Trial Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Safety and efficacy of the bnt162b2 mrna covid-19 vaccine</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Geginat</surname><given-names>J</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Central memory and effector memory T cell subsets: function, generation, and maintenance</article-title><source>Annual Review of Immunology</source><volume>22</volume><fpage>745</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104702</pub-id><pub-id pub-id-type="pmid">15032595</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekine</surname><given-names>T</given-names></name><name><surname>Perez-Potti</surname><given-names>A</given-names></name><name><surname>Rivera-Ballesteros</surname><given-names>O</given-names></name><name><surname>Strålin</surname><given-names>K</given-names></name><name><surname>Gorin</surname><given-names>J-B</given-names></name><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Llewellyn-Lacey</surname><given-names>S</given-names></name><name><surname>Kamal</surname><given-names>H</given-names></name><name><surname>Bogdanovic</surname><given-names>G</given-names></name><name><surname>Muschiol</surname><given-names>S</given-names></name><name><surname>Wullimann</surname><given-names>DJ</given-names></name><name><surname>Kammann</surname><given-names>T</given-names></name><name><surname>Emgård</surname><given-names>J</given-names></name><name><surname>Parrot</surname><given-names>T</given-names></name><name><surname>Folkesson</surname><given-names>E</given-names></name><collab>Karolinska COVID-19 Study Group</collab><name><surname>Rooyackers</surname><given-names>O</given-names></name><name><surname>Eriksson</surname><given-names>LI</given-names></name><name><surname>Henter</surname><given-names>J-I</given-names></name><name><surname>Sönnerborg</surname><given-names>A</given-names></name><name><surname>Allander</surname><given-names>T</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Klingström</surname><given-names>J</given-names></name><name><surname>Gredmark-Russ</surname><given-names>S</given-names></name><name><surname>Björkström</surname><given-names>NK</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Ljunggren</surname><given-names>H-G</given-names></name><name><surname>Aleman</surname><given-names>S</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Robust t cell immunity in convalescent individuals with asymptomatic or mild covid-19</article-title><source>Cell</source><volume>183</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id><pub-id pub-id-type="pmid">32979941</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Coelho</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>Methot</surname><given-names>N</given-names></name><name><surname>Bloom</surname><given-names>NI</given-names></name><name><surname>Goodwin</surname><given-names>B</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Filaci</surname><given-names>G</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>da Silva Antunes</surname><given-names>R</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron</article-title><source>Cell</source><volume>185</volume><fpage>847</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.015</pub-id><pub-id pub-id-type="pmid">35139340</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terahara</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Tonouchi</surname><given-names>K</given-names></name><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Moriyama</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Kawana-Tachikawa</surname><given-names>A</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Shinkai</surname><given-names>M</given-names></name><name><surname>Isogawa</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2-specific CD4<sup>+</sup> T cell longevity correlates with Th17-like phenotype</article-title><source>iScience</source><volume>25</volume><elocation-id>104959</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2022.104959</pub-id><pub-id pub-id-type="pmid">35992306</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dang</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves’ orbitopathy</article-title><source>Cellular &amp; Molecular Immunology</source><volume>18</volume><fpage>735</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-00615-2</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolock</surname><given-names>SL</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Scrublet: Computational identification of cell doublets in single-cell transcriptomic data</article-title><source>Cell Systems</source><volume>8</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.11.005</pub-id><pub-id pub-id-type="pmid">30954476</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>E</given-names></name><name><surname>Sakuma</surname><given-names>M</given-names></name><name><surname>Ogata</surname><given-names>K</given-names></name><name><surname>Sakata-Sogawa</surname><given-names>K</given-names></name><name><surname>Hiroshima</surname><given-names>M</given-names></name><name><surname>Wiest</surname><given-names>DL</given-names></name><name><surname>Tokunaga</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mechanistic basis of pre-T cell receptor-mediated autonomous signaling critical for thymocyte development</article-title><source>Nature Immunology</source><volume>7</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/ni1290</pub-id><pub-id pub-id-type="pmid">16327787</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>C</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Shiraishi</surname><given-names>S</given-names></name><name><surname>Tomono</surname><given-names>K</given-names></name><name><surname>Arase</surname><given-names>H</given-names></name><name><surname>Matsuura</surname><given-names>Y</given-names></name><name><surname>Nakagami</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>5934</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-85202-9</pub-id><pub-id pub-id-type="pmid">33723294</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Lei</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>YP</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals</article-title><source>Nature Microbiology</source><volume>6</volume><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00824-5</pub-id><pub-id pub-id-type="pmid">33199863</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89999.4.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Morio</surname><given-names>Tomohiro</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Tokyo Medical and Dental University</institution><country>Japan</country></aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study by Lu et al aimed to determine the key factors of T cell responses associated with durable antibody responses following the initial two shots of COVID-19 mRNA vaccinations. By comparing the SARS-CoV-2 spike protein (S)-specific T cell subsets between ‘Ab sustainers’ and ‘Ab decliners’ that were present post-vaccination, the authors concluded that S-specific CD4<sup>+</sup> T cells in ‘Ab sustainers’ were enriched with Tfh cells. There is <bold>solid</bold> evidence as the authors applied multiple methods and approaches to address the key questions, and the presented data are robust.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89999.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>• A summary of what the authors were trying to achieve.</p><p>The authors cultured pre- and Post-vaccine PBMCs with overlapping peptides encoding S protein in the presence of IL-2, IL-7, and IL-15 for 10 days, and extensively analyzed the T cells expanded during the culture; by including scRNAseq, scTCRseq, and examination of reporter cell lines expressing the dominant TCRs. They were able to identify 78 S epitopes with HLA restrictions (by itself represents a major achievement) together with their subset, based on their transcriptional profiling. By comparing T cell clonotypes between pre- and post-vaccination samples, they showed that a majority of pre-existing S-reactive CD4+ T cell clones did not expand by vaccinations. Thus, the authors concluded that highly-responding S-reactive T cells were established by vaccination from rare clonotypes.</p><p>• An account of the major strengths and weaknesses of the methods and results.</p><p>Strengths</p><p>• Selection of 4 &quot;Ab sustainers&quot; and 4 &quot;Ab decliners&quot; from 43 subjects who received two shots of mRNA vaccinations.</p><p>• Identification of S epitopes of T cells together with their transcriptional profiling. This allowed the authors to compare the dominant subsets between sustainers and decliners.</p><p>Weaknesses were adequately addressed in the revised manuscript, and I do not have any additional concerns.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89999.4.sa2</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The paper aims to investigate the relationship between anti-S protein antibody titers with the phenotypes &amp; clonotypes of S-protein-specific T cells in people who receive SARS-CoV2 mRNA vaccines. The paper recruited a cohort of COVID-19 naive individuals who received the SARS-CoV2 mRNA vaccines and collected sera and PBMCs samples on different time points. Then, three sets of data were generated: (1). Anti-S protein antibody titers on all time points. (2) Single-cell RNAseq/TCRseq analysis for divided T cells after in vitro stimulation by S-protein. (3) Peptide epitopes for each expanded TCR clone. Based on these, the paper reports two major findings: (A) Individuals having more sustained anti-S protein antibody response also have more Tfh-featured S-specific cells in their blood after 2nd-dose vaccination. (B). S-specific cross-reactive T cells exist in COVID-19 naive individuals, but most of these T cell clones are not expanded after SARS-CoV-2 vaccination.</p><p>The paper's strength is that it uses a very systemic strategy trying to dissect the relationship between antibody titers, T cell phenotypes, TCR clonotypes and corresponding epitopes. The conclusion is solid in general. However, the weaknesses include the relatively small sample size (4 sustainers vs. 4 decliners) and the use of in vitro stimulated cells for analysis, which may 'blur' the classification of T cell subsets. Nevertheless, it may have great impact on future vaccine design because it demonstrated that promoting Tfh differentiation is crucial for the longevity of antibody response. Additionally, this paper nicely showed that most cross-reactive clones that are specific to environmental/symbiotic microbes did not expand post- vaccination, providing important fundamental insights into the establishment of T-cell responses after SARS-CoV-2 vaccination.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89999.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Xiuyuan</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University</institution><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hayashi</surname><given-names>Hiroki</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University</institution><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Ishikawa</surname><given-names>Eri</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University</institution><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Takeuchi</surname><given-names>Yukiko</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University</institution><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Dychiao</surname><given-names>Julian Vincent Tabora</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University</institution><addr-line><named-content content-type="city">Suita</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Nakagami</surname><given-names>Hironori</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University United Graduate School of Child Development</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Yamasaki</surname><given-names>Sho</given-names></name><role specific-use="author">Author</role><aff><institution>Osaka University</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>A summary of what the authors were trying to achieve.</p><p>The authors cultured pre- and Post-vaccine PBMCs with overlapping peptides encoding S protein in the presence of IL-2, IL-7, and IL-15 for 10 days, and extensively analyzed the T cells expanded during the culture; by including scRNAseq, scTCRseq, and examination of reporter cell lines expressing the dominant TCRs. They were able to identify 78 S epitopes with HLA restrictions (by itself represents a major achievement) together with their subset, based on their transcriptional profiling. By comparing T cell clonotypes between pre- and post-vaccination samples, they showed that a majority of pre-existing S-reactive CD4+ T cell clones did not expand by vaccinations. Thus, the authors concluded that highly-responding S-reactive T cells were established by vaccination from rare clonotypes.</p><p>An account of the major strengths and weaknesses of the methods and results.</p></disp-quote><p>Strengths:</p><disp-quote content-type="editor-comment"><p>Selection of 4 &quot;Ab sustainers&quot; and 4 &quot;Ab decliners&quot; from 43 subjects who received two shots of mRNA vaccinations.</p><p>Identification of S epitopes of T cells together with their transcriptional profiling. This allowed the authors to compare the dominant subsets between sustainers and decliners.</p><p>Weaknesses were properly addressed in the revised manuscript, and I do not have any additional concerns.</p></disp-quote><p>We appreciate the reviewer for the constructive comments and recommendations, which were a great help for us to improve our manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>The paper aims to investigate the relationship between anti-S protein antibody titers with the phenotypes&amp;clonotypes of S-protein-specific T cells, in people who receive SARS-CoV2 mRNA vaccines. To do this, the paper recruited a cohort of Covid-19 naive individuals that receives the SARS-CoV2 mRNA vaccines and collect sera and PBMCs samples on different timepoints. Then they mainly generate three sets of data: (1). Anti-S protein antibody titers on all timepoints. (2) Single-cell RNAseq/TCRseq dataset for divided T cells after stimulation by Sprotein for 10 days. (3) Corresponding epitopes for each expanded TCR clones. After analyzing these result, the paper reports two major findings&amp;claims: (A) Individuals having sustained anti-S protein antibody response also have more so-called Tfh cells in their single-cell dataset. (B). S-reactive T cells do exist before the vaccination, but they seems to be unable to response to Covid-19 vaccination properly.</p><p>The paper's strength is it uses a very systemic and thorough strategy trying to dissect the relationship between antibody titers, T cell phenotypes, TCR clonotypes and corresponding epitopes, and indeed it reports several interesting findings about the relationship of Tfh clonotypes/sustained antibody and about the S-reactive clones that exist before the vaccination. The conclusion is solid in general but some claims are overstated. My suggestion is the authors should further limit their claims in abstract, for example,</p><p>”Even before vaccination, S-reactive CD4+ T cell clonotypes did exist, most of which (MAY) cross-reacted with environmental or symbiotic bacteria&quot; -- The paper don't have experimental evidence to show these TCR clones respond to these epitopes.</p></disp-quote><p>We thank the reviewer for pointing out the insufficient demonstration of experimental evidence. We have added the relevant data to Fig. S5 in the newly revised manuscript.</p><disp-quote content-type="editor-comment"><p>&quot;These results suggest that de novo acquisition of memory Tfh-like cells upon vaccination (LIKELY) contributes to the longevity of anti-S antibody titers.&quot; --Given the small sample size and the statistical analysis was not significant, this claim was overstated.</p><p>&quot;S-reactive T cell clonotypes detected immediately after 2nd vaccination polarized to follicular helper T (Tfh)-like cells (UNDER IN VITRO CULTURE)&quot;. -- the conclusion was based on vitro cultured cells, which had limitation.</p></disp-quote><p>We thank the reviewer for the helpful suggestion. We have corrected some sentences in line with these suggestions in the newly revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p>Please note: Though most of the overstatement was removed from the original manuscript, authors still need to modify some of the statements in &quot;Abstract&quot;.</p></disp-quote><p>We thank the reviewer for carefully reading our manuscript and giving us detailed suggestions. We have modified these statements in “Abstract” accordingly in the newly revised manuscript.</p></body></sub-article></article>